<SEC-DOCUMENT>0001628908-23-000169.txt : 20231103
<SEC-HEADER>0001628908-23-000169.hdr.sgml : 20231103
<ACCEPTANCE-DATETIME>20231102200923
ACCESSION NUMBER:		0001628908-23-000169
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20231102
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20231103
DATE AS OF CHANGE:		20231102

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Evolent Health, Inc.
		CENTRAL INDEX KEY:			0001628908
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MANAGEMENT SERVICES [8741]
		IRS NUMBER:				320454912
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37415
		FILM NUMBER:		231374135

	BUSINESS ADDRESS:	
		STREET 1:		800 NORTH GLEBE RD, SUITE 500
		CITY:			ARLINGTON
		STATE:			VA
		ZIP:			22203
		BUSINESS PHONE:		571-389-6000

	MAIL ADDRESS:	
		STREET 1:		800 NORTH GLEBE RD, SUITE 500
		CITY:			ARLINGTON
		STATE:			VA
		ZIP:			22203
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>evh-20231102.htm
<DESCRIPTION>11.02.23 8-K (NIA)
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with the Workiva Platform--><!--Copyright 2023 Workiva--><!--r:90e52ce1-dec2-482d-8850-7e0869b345ac,g:fa62104d-c26f-4dc4-a3b6-8e40cb2ba55f,d:0ebfe62b4ddf41ccae978f661d7d38e9--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>evh-20231102</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-22">November 2, 2023</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-23">0001628908</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-24">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="evh-20231102.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-02</xbrli:startDate><xbrli:endDate>2023-11-02</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i0ebfe62b4ddf41ccae978f661d7d38e9_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">_________________________</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">_________________________</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pursuant to Section 13 or 15(d) of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Securities Exchange Act of 1934 </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">November 2, 2023</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported)  &#160;&#160;</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Evolent Health, Inc.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">_________________________</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.333%"><tr><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.472%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-37415</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">32-0454912</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commission File Number:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">800 N. Glebe Road</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-8">Suite 500</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-9">Arlington</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-10">Virginia</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">22203</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of principal executive offices)(zip code)</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-12">571</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-13">389-6000</ix:nonNumeric>  </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Not Applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Former name, former address and former fiscal year, if changed since last report.)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">_________________________</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric>  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric>  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric>  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-17">&#9744;</ix:nonNumeric>  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"></td><td style="width:31.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.770%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-18">Class A Common Stock of Evolent Health, Inc., par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-19">EVH</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-20">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Emerging growth company <ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-21">&#9744;</ix:nonNumeric> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744; </span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i0ebfe62b4ddf41ccae978f661d7d38e9_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div id="i0ebfe62b4ddf41ccae978f661d7d38e9_92"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Item 8.01.  Other Events.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This Current Report on Form 8-K is being filed by Evolent Health, Inc. (the &#8220;Company&#8221;) with the Securities and Exchange Commission to include (i) audited combined financial statements of Magellan Specialty Health (a business of Magellan Health, Inc.) (&#8220;Magellan&#8221;) and certain of its subsidiaries that were used in the Magellan specialty health division (&#8220;NIA&#8221;) as of and for the year ended December 31, 2022 attached as Exhibit 99.1 and (ii) the unaudited pro forma financial information attached as Exhibit 99.2.</span></div><div><span><br/></span></div><div id="i0ebfe62b4ddf41ccae978f661d7d38e9_10"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Item 9.01.  Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(a)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Financial Statements of Business Acquired.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The audited financial statements of NIA, comprised of the combined balance sheet as of December 31, 2022, the related combined statements of income, cash flows and net parent investment for the year ended December 31, 2022 and the related notes to the combined financial statements, are attached hereto as Exhibit 99.1.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Pro Forma Financial Information.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Unaudited pro forma condensed combined financial information of the Company as of and for year ended December 31, 2022 and for the nine months ended September 30, 2023, giving effect to the Company&#8217;s acquisition of NIA, is attached hereto as Exhibit 99.2. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(d)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Exhibits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.269%"><tr><td style="width:1.0%"></td><td style="width:14.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.487%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit231marcumconsent.htm">23.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit231marcumconsent.htm">Consent of Marcum, LLP.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit9912022niaaudit.htm">99.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit9912022niaaudit.htm">Combined A</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit9912022niaaudit.htm">udited financial statements of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit9912022niaaudit.htm">NIA</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit9912022niaaudit.htm"> as of and for the year ended December 31, 2022.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit992niaproforma.htm">99.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit992niaproforma.htm">Unaudited pro forma condensed combined financial information of Evolent Health, Inc., as of and for the year ended December 31, 2022 and for the nine months ended September 30, 2023. </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The cover page from this Current Report on Form 8-K, formatted as Inline XBRL.</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i0ebfe62b4ddf41ccae978f661d7d38e9_13"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SIGNATURES </span></div><div style="text-indent:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date: November 2, 2023</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.269%"><tr><td style="width:1.0%"></td><td style="width:19.270%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.530%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EVOLENT HEALTH, INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;/s/ Jonathan Weinberg</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jonathan Weinberg</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General Counsel and Secretary</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>exhibit231marcumconsent.htm
<DESCRIPTION>EX-23.1 CONSENT
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i942c761bc7ed44b282bd6ddab3e1a497_34"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM&#8217;S CONSENT</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We consent to the incorporation by reference in the registration statements Nos. 333-212709 and 333-266495 on Form S-3 and in the registration statements Nos. 333-204785, 333-225714 and 333-257118 on Form S-8 of Evolent Health, Inc. of our report dated October 31, 2023, with respect to our audit of the combined financial statements of Magellan Specialty Health (a business of Magellan Health, Inc.) as of December 31, 2022 and for the year then ended, which report appears in this Current Report on Form 8-K filed by Evolent Health, Inc. with the SEC on November 2, 2023.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#47;s&#47; Marcum LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Marcum LLP</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">New York, NY</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">November 2, 2023</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>exhibit9912022niaaudit.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i4aecff12a8ec4e16a82838a8038239a2_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 99.1</font></div></div><div style="margin-top:0.15pt;text-align:right"><img alt="magellanlogoa.jpg" src="magellanlogoa.jpg" style="height:182px;margin-bottom:5pt;vertical-align:text-bottom;width:441px"></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14.5pt;font-weight:400;line-height:100%">COMBINED FINANCIAL STATEMENTS</font></div><div style="margin-top:0.15pt;text-align:center"><font><br></font></div><div style="margin-top:0.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14.5pt;font-weight:400;line-height:100%">MAGELLAN SPECIALTY HEALTH</font></div><div style="margin-top:0.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14.5pt;font-weight:400;line-height:100%">(A Business of Magellan Health, Inc.)</font></div><div style="margin-top:0.15pt;text-align:center"><font><br></font></div><div style="margin-top:0.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14.5pt;font-weight:400;line-height:100%">December 31, 2022</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><div id="i4aecff12a8ec4e16a82838a8038239a2_4"></div><hr style="page-break-after:always"><div style="min-height:82.8pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">MAGELLAN SPECIALTY HEALTH</font></div><div style="margin-top:0.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A Business of Magellan Health, Inc.)</font></div><div style="margin-top:0.15pt;text-align:center"><font><br></font></div><div style="margin-top:0.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">COMBINED FINANCIAL STATEMENTS</font></div><div style="margin-top:0.15pt;text-align:center"><font><br></font></div><div style="margin-top:0.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Year Ended December 31, 2022</font></div><div style="margin-bottom:16pt;margin-top:56pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Contents</font></div><div style="margin-bottom:14pt;padding-left:9.35pt;padding-right:54pt;text-indent:-9.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Report of Independent Auditors&#160;&#160;&#160;&#160;1</font></div><div style="margin-bottom:14pt;margin-top:14pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audited Financial Statements</font></div><div style="padding-left:9.35pt;padding-right:54pt;text-indent:-9.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined Balance Sheet&#160;&#160;&#160;&#160;3</font></div><div style="padding-left:9.35pt;padding-right:54pt;text-indent:-9.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined Statement of Income&#160;&#160;&#160;&#160;4</font></div><div style="padding-left:9.35pt;padding-right:54pt;text-indent:-9.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined Statement of Net Parent Investment&#160;&#160;&#160;&#160;5</font></div><div style="padding-left:9.35pt;padding-right:54pt;text-indent:-9.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined Statement of Cash Flows&#160;&#160;&#160;&#160;6</font></div><div style="padding-left:9.35pt;padding-right:54pt;text-indent:-9.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes to Combined Financial Statements&#160;&#160;&#160;&#160;7</font></div><div style="margin-top:0.15pt;text-align:center"><font><br></font></div><div style="margin-top:0.15pt;text-align:center"><font><br></font></div><div style="margin-top:0.15pt;text-align:center"><font><br></font></div><div style="margin-top:0.15pt;text-align:center"><font><br></font></div><div style="margin-top:0.15pt;text-align:center"><font><br></font></div><div style="margin-top:0.15pt;text-align:center"><font><br></font></div><div style="margin-top:0.15pt;text-align:center"><font><br></font></div><div style="margin-top:0.15pt;text-align:center"><font><br></font></div><div style="margin-top:0.15pt;text-align:center"><font><br></font></div><div style="margin-top:0.15pt;text-align:center"><font><br></font></div><div style="margin-top:0.15pt;text-align:center"><font><br></font></div><div style="margin-top:0.15pt;text-align:center"><font><br></font></div><div style="margin-top:0.15pt;text-align:center"><font><br></font></div><div style="margin-top:0.15pt;text-align:center"><font><br></font></div><div style="margin-top:0.15pt;text-align:center"><font><br></font></div><div style="margin-top:0.15pt;text-align:center"><font><br></font></div><div style="height:25.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><div id="i4aecff12a8ec4e16a82838a8038239a2_7"></div><hr style="page-break-after:always"><div style="min-height:82.8pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">INDEPENDENT AUDITORS&#8217; REPORT</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To the Stockholders and Board of Directors of </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Magellan Specialty Health (A Business of Magellan Health, Inc.)</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Opinion</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have audited the combined financial statements of Magellan Specialty Health (A Business of Magellan Health, Inc.) which comprise the combined balance sheet as of December 31, 2022, and the related combined statements of income, net parent investment and cash flows for the year then ended, and the related notes to the financial statements.  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In our opinion, the accompanying combined financial statements present fairly, in all material respects, the combined financial position of Magellan Specialty Health (A Business of Magellan Health, Inc) as of December 31, 2022, and the combined results of its operations and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Basis for Opinion</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We conducted our audit in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the Auditors&#8217; Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of Magellan Specialty Health (A Business of Magellan Health, Inc.) and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Responsibilities of Management for the Financial Statements</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about Magellan Specialty Health&#8217;s (A Business of Magellan Health, Inc.) ability to continue as a going concern within one year after the date that the financial statements are available to be issued.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Auditors&#8217; Responsibilities for the Audit of the Financial Statements</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors&#8217; report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In performing an audit in accordance with GAAS, we&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.51pt">Exercise professional judgment and maintain professional skepticism throughout the audit.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.51pt">Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.51pt">Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of Magellan Specialty Health&#8217;s (A Business of Magellan Health, Inc.) internal control. Accordingly, no such opinion is expressed.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.51pt">Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.</font></div><div style="height:25.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:82.8pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-36.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.51pt">Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about Magellan Specialty Health&#8217;s (A Business of Magellan Health, Inc.) ability to continue as a going concern for a reasonable period of time.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#47;s&#47; Marcum LLP</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">New York City, NY</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">October 31, 2023</font></div><div style="height:25.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><div id="i4aecff12a8ec4e16a82838a8038239a2_77"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.6pt;padding-left:1.72pt;padding-right:1.72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MAGELLAN SPECIALTY HEALTH</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(A Business of Magellan Health, Inc.)</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:123.9pt;padding-right:123.9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMBINED BALANCE SHEET AS OF DECEMBER 31, 2022</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:1.72pt;padding-right:1.72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.515%"><tr><td style="width:1.0%"></td><td style="width:80.061%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.421%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.218%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</font></td><td colspan="3" style="background-color:#ccedff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccedff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Assets&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</font></td><td colspan="3" style="background-color:#ccedff;padding:0 1pt"></td><td style="background-color:#ccedff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ccedff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ccedff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,115</font></td></tr><tr><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts due from affiliates, net</font></td><td colspan="3" style="background-color:#ccedff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,002</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">770</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Current Assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,887</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,009</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,214</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets, net</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</font></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,763&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Liabilities&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,299</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Current Liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,819</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,428</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Parent investment</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,335</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities and Equity</font></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,763&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:140.05pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:140.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">See accompanying notes to Combined Financial Statements.<br><br></font></div><div style="margin-top:4.6pt;padding-left:140.05pt"><font><br></font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:140.05pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:140.05pt"><font><br></font></div><div style="margin-top:0.45pt;padding-left:1.97pt;padding-right:1.97pt;text-align:center"><font><br></font></div><div style="margin-top:0.45pt;padding-left:1.97pt;padding-right:1.97pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><br><br><br><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:1.97pt;padding-right:1.97pt;text-align:center"><font><br></font></div><div style="margin-top:0.3pt;text-align:center"><font><br></font></div><div style="margin-top:4.6pt;padding-left:1.72pt;padding-right:1.72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MAGELLAN SPECIALTY HEALTH</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(A Business of Magellan Health, Inc.)</font></div><div style="margin-top:0.35pt;text-align:center"><font><br></font></div><div style="padding-left:123.9pt;padding-right:123.9pt;text-align:center;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMBINED STATEMENT OF INCOME FOR THE YEAR ENDED DECEMBER 31, 2022</font></div><div style="margin-top:0.5pt;text-align:center"><font><br></font></div><div style="padding-left:1.72pt;padding-right:1.72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</font></div><div style="margin-top:0.4pt;text-align:center"><font><br></font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:39.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.539%"><tr><td style="width:1.0%"></td><td style="width:76.933%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.874%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.893%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care and other</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,298&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenue</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,298</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct service costs and other operating expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,043</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,866</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,909</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,389</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,128</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</font></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,261&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:8.45pt"><img alt="image_1a.jpg" src="image_1a.jpg" style="height:1px;margin-bottom:5pt;vertical-align:text-bottom;width:148px"></div><div style="margin-top:2.55pt;padding-left:40.55pt;padding-right:22.25pt;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Includes stock compensation expense of $774 for the year ended December 31, 2022. Refer to Note 2 &#34;Summary of Significant Accounting Policies&#34; for further detail. </font></div><div style="margin-top:2.55pt;padding-left:40.55pt;padding-right:22.25pt"><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:1.72pt;padding-right:1.72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">See accompanying notes to Combined Financial Statements.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:1.97pt;padding-right:1.97pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><br><br></font></div><div style="padding-left:1.97pt;padding-right:1.97pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><br><br></font></div><div style="padding-left:1.97pt;padding-right:1.97pt;text-align:center"><font><br></font></div><div style="padding-left:1.97pt;padding-right:1.97pt;text-align:center"><font><br></font></div><div style="padding-left:1.97pt;padding-right:1.97pt;text-align:center"><font><br></font></div><div style="padding-left:1.97pt;padding-right:1.97pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><br></font></div><div style="padding-left:1.97pt;padding-right:1.97pt;text-align:center"><font><br></font></div><div style="padding-left:1.97pt;padding-right:1.97pt;text-align:center"><font><br></font></div><div style="padding-left:1.97pt;padding-right:1.97pt;text-align:center"><font><br></font></div><div style="padding-left:1.97pt;padding-right:1.97pt;text-align:center"><font><br></font></div><div style="padding-left:1.97pt;padding-right:1.97pt;text-align:center"><font><br></font></div><div style="padding-left:1.97pt;padding-right:1.97pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:1.97pt;padding-right:1.97pt;text-align:center"><font><br></font></div><div style="padding-left:1.97pt;padding-right:1.97pt;text-align:center"><font><br></font></div><div style="padding-left:1.97pt;padding-right:1.97pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><br></font></div><div style="padding-left:1.97pt;padding-right:1.97pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MAGELLAN SPECIALTY HEALTH</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(A Business of Magellan Health, Inc.)</font></div><div style="margin-bottom:0.35pt;margin-top:6.7pt;padding-left:64.22pt;padding-right:64.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:242%">COMBINED STATEMENT OF NET PARENT INVESTMENT</font></div><div style="padding-left:1.72pt;padding-right:1.72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.125%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.030%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</font></td></tr><tr><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</font></td><td colspan="3" style="background-color:#ccedff;padding:0 1pt"></td><td style="background-color:#ccedff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ccedff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,857&#160;</font></td><td style="background-color:#ccedff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation expense</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</font></td><td colspan="3" style="background-color:#ccedff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccedff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,261&#160;</font></td><td style="background-color:#ccedff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net transfers to Parent</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,557)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2022</font></td><td colspan="3" style="background-color:#ccedff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,335&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:1.72pt;padding-right:1.72pt;text-align:center"><font><br></font></div><div style="padding-left:1.72pt;padding-right:1.72pt;text-align:center"><font><br></font></div><div style="padding-left:1.72pt;padding-right:1.72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">See accompanying notes to Combined Financial Statements.</font></div><div style="margin-top:0.05pt;padding-left:1.72pt;padding-right:1.72pt;text-align:center"><font><br></font></div><div style="margin-top:0.05pt;padding-left:1.72pt;padding-right:1.72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><br></font></div><div style="margin-top:0.05pt;padding-left:1.72pt;padding-right:1.72pt;text-align:center"><font><br></font></div><div style="margin-top:0.05pt;padding-left:1.72pt;padding-right:1.72pt;text-align:center"><font><br></font></div><div style="margin-top:0.05pt;padding-left:1.72pt;padding-right:1.72pt;text-align:center"><font><br></font></div><div style="margin-top:0.05pt;padding-left:1.72pt;padding-right:1.72pt;text-align:center"><font><br></font></div><div style="margin-top:0.05pt;padding-left:1.72pt;padding-right:1.72pt;text-align:center"><font><br></font></div><div style="margin-top:0.05pt;padding-left:1.72pt;padding-right:1.72pt;text-align:center"><font><br></font></div><div style="margin-top:0.05pt;padding-left:1.72pt;padding-right:1.72pt;text-align:center"><font><br></font></div><div style="margin-top:0.05pt;padding-left:1.72pt;padding-right:1.72pt;text-align:center"><font><br></font></div><div style="margin-top:0.05pt;padding-left:1.72pt;padding-right:1.72pt;text-align:center"><font><br></font></div><div style="margin-top:0.05pt;padding-left:1.72pt;padding-right:1.72pt;text-align:center"><font><br></font></div><div style="margin-top:0.05pt;padding-left:1.72pt;padding-right:1.72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><br><br><br></font></div><div style="margin-top:0.05pt;padding-left:1.72pt;padding-right:1.72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><br><br><br><br><br></font></div><div style="margin-top:0.05pt;padding-left:1.72pt;padding-right:1.72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><br></font></div><div style="margin-top:0.05pt;padding-left:1.72pt;padding-right:1.72pt;text-align:center"><font><br></font></div><div style="margin-top:0.05pt;padding-left:1.72pt;padding-right:1.72pt;text-align:center"><font><br></font></div><div style="margin-top:0.05pt;padding-left:1.72pt;padding-right:1.72pt;text-align:center"><font><br></font></div><div style="margin-top:0.05pt;padding-left:1.72pt;padding-right:1.72pt;text-align:center"><font><br></font></div><div style="margin-top:0.05pt;padding-left:1.72pt;padding-right:1.72pt;text-align:center"><font><br></font></div><div style="margin-top:0.05pt;padding-left:1.72pt;padding-right:1.72pt;text-align:center"><font><br></font></div><div style="margin-top:0.05pt;padding-left:1.72pt;padding-right:1.72pt;text-align:center"><font><br></font></div><div style="margin-top:0.05pt;padding-left:1.72pt;padding-right:1.72pt;text-align:center"><font><br></font></div><div style="margin-top:0.05pt;padding-left:1.72pt;padding-right:1.72pt;text-align:center"><font><br></font></div><div style="margin-top:0.05pt;padding-left:1.72pt;padding-right:1.72pt;text-align:center"><font><br></font></div><div style="margin-top:0.05pt;padding-left:1.72pt;padding-right:1.72pt;text-align:center"><font><br></font></div><div style="margin-top:0.05pt;padding-left:1.72pt;padding-right:1.72pt;text-align:center"><font><br></font></div><div style="margin-top:0.05pt;padding-left:1.72pt;padding-right:1.72pt;text-align:center"><font><br></font></div><div style="margin-top:0.05pt;padding-left:1.72pt;padding-right:1.72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:1.72pt;padding-right:1.72pt;text-align:center"><font><br></font></div><div style="margin-top:6.7pt;padding-left:1.72pt;padding-right:1.72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MAGELLAN SPECIALTY HEALTH</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(A Business of Magellan Health, Inc.)</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:1.72pt;padding-right:1.72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">COMBINED STATEMENT OF CASH FLOWS </font></div><div style="padding-left:1.72pt;padding-right:1.72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FOR THE YEAR ENDED DECEMBER 31, 2022</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:1.72pt;padding-right:1.72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:38.71pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.515%"><tr><td style="width:1.0%"></td><td style="width:80.061%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.421%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.218%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,261&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash from operating activities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,866&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash stock compensation expense</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash income tax provision</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(975)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in assets and liabilities, net of effects from acquisitions of businesses&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,253&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts due from affiliates, net</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,110&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,995)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,023&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">59,317</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,760)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,760)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net transfers (to) from Parent</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,557)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(54,557)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash at beginning of period</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash at end of period</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:8.45pt"><font><br></font></div><div style="padding-left:305.4pt"><font><br></font></div><div><font><br></font></div><div style="margin-top:4.7pt;padding-left:1.72pt;padding-right:1.72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">See accompanying notes to Combined Financial Statements.</font></div><div><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><br><br><br><br><br><br><br><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.15pt;text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="margin-top:0.15pt;text-align:center"><font><br></font></div><div style="margin-top:0.15pt;text-align:center"><font><br></font></div><div style="margin-top:0.15pt;text-align:center"><font><br></font></div><div style="margin-top:0.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MAGELLAN SPECIALTY HEALTH</font></div><div style="margin-top:0.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(A business of Magellan Health, Inc.)     </font></div><div style="margin-top:6.7pt;padding-left:115.02pt;padding-right:115.02pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:242%">NOTES TO COMBINED FINANCIAL STATEMENTS</font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;Organization and Nature of Operations</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying combined carve-out financial statements include the historical accounts of Magellan Specialty Health (referred to as Specialty Health or the &#8220;Company&#8221;), part of the Healthcare segment of Magellan Health, Inc. (&#34;Magellan&#34; or the &#34;Parent&#34;). Magellan was acquired by, and became a wholly owned subsidiary of, Centene Corporation (&#8220;Centene&#8221;) effective as of January 4, 2022.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 17, 2022, Magellan Health, Inc. and Magellan Healthcare, Inc. executed a definitive agreement to sell Magellan&#8217;s Specialty Health business to Evolent Health, Inc. (&#8220;Evolent&#8221;) (collectively the &#8220;Sale&#8221;). Given MPT and MLIC no longer have any specialty business, the only legal entities included in the Sale are NIA and its non-dissolved subsidiaries. The Sale closed on January 20, 2023.  In addition to the Sale, Evolent and Centene are expanding Centene&#8217;s relationship with NIA and extending NIA&#8217;s contracts with Centene through 2027. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is focused on delivering innovative specialty solutions for the fastest growing, most complex areas of healthcare. The Company develops innovative solutions that combine advanced analytics, agile technology and clinical excellence to drive better decision making and positively impact members' health outcomes. The Company provides its management services primarily through&#58; (i) risk-based contractual arrangements or (ii) administrative services only (&#8220;ASO&#8221;) contractual arrangements. Additional information regarding the Company&#8217;s contractual arrangements is provided in &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; below.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s customers include health plans for whom Magellan provides carve-out management services for areas of specialty healthcare including diagnostic imaging, musculoskeletal management, cardiac and physical medicine. These management services can be applied broadly across commercial, Medicaid and Medicare populations, or on a more targeted basis for our health plan customers. </font></div><div style="padding-right:15.05pt;text-align:justify"><font><br></font></div><div style="margin-top:4.6pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies</font></div><div style="margin-top:0.3pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</font></div><div style="margin-top:0.3pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Combined Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (&#34;U.S. GAAP&#34;) from the consolidated financial statements and accounting records of Magellan using the historical results of operations and historical cost basis of the assets and liabilities of Magellan that comprise Specialty Health. The Company has historically operated as part of Magellan and not as a stand-alone company and has no separate legal status or existence. Consequently, stand-alone financial statements have not historically been prepared by Specialty Health. The accompanying Combined Financial Statements have been prepared from Magellan&#8217;s historical consolidated financial statements and accounting records and are presented on a stand-alone basis as if the Company&#8217;s operations had been conducted independently from Magellan. All intercompany accounts within Specialty Health have been eliminated within these statements.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operations comprising Specialty Health are in various legal entities, owned 100% by the Parent, in which Specialty Health has no direct ownership relationship. References in these Combined Financial Statements to subsidiaries of Magellan Specialty Health refers to legal entities that are primarily engaged in operating activities that are dedicated to the business of Specialty Health. The Company&#8217;s business is primarily composed of all of the business of National Imaging Associates, Inc. (&#8220;NIA&#8221;), as well as the specialty risk business written by Magellan Providers of Texas, Inc. (&#8220;MPT&#8221;) and Magellan Life Insurance Company (&#8220;MLIC&#8221;). Effective January 1, 2022, the risk business written by MPT and MLIC converted to non-risk contracts.  This non-risk business is written by NIA as of January 1, 2022. The financial statements have been derived from Magellan's historical accounting records and are presented on a carve-out basis. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Combined Statement of Income include revenues and costs directly attributable to Specialty Health as well as an allocation of expenses related to functions and services provided by our Parent. The allocation methodologies have been described within the notes to the Combined Financial Statements where appropriate. These allocated costs are primarily related to corporate administrative expenses, and other corporate support services.   The allocated costs are deemed to be settled by Specialty Health to the Parent in the period in which the expense was recorded in the Combined Statement of Income. The Combined Statement of Cash Flows present these allocated Parent functional costs as cash flows from operating activities. Due to the inherent limitation of allocations, there can be no assurance that allocated costs represent arm&#8217;s length transactions.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current and deferred income taxes and related tax expense have been determined based on the stand-alone results of the Company by applying Accounting Standards Codification No. 740,&#160;Income Taxes&#160;(&#8220;ASC 740&#8221;), to Specialty Health&#8217;s operations as if it was a separate taxpayer (i.e. following the Separate Return Methodology).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Combined Balance Sheets include all assets and liabilities that are attributable to the Specialty Health business. Assets and liabilities in shared entities were included in the stand-alone financial statements to the extent the asset is primarily used by Specialty Health. If Specialty Health is not the primary user of the asset, it was excluded entirely from the Combined Financial Statements. Any such items which exist in other entities, whether shared or otherwise, are outside of the control of Specialty Health and have been excluded from the Combined Financial Statements. Our Parent&#8217;s third-party debt and the related interest have not been allocated to us for any of the periods presented because our Parent&#8217;s borrowings are primarily for corporate cash purposes and are not directly attributable to the Company. In addition, the Company did not guarantee the debt nor is the Company jointly and severally liable for Parent's debt.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the Parent&#8217;s centralized processes and systems for cash management, payroll, purchasing, and distribution. Accordingly, cash, related party debt and related party interest have been attributed to Specialty Health in the Combined Financial Statement only to the extent such items have been legally entitled to the Company. The net results of these cash transactions between the Company and the Parent are reflected within net Parent investment in the accompanying combined balance sheets. In addition, net Parent investment represents the Parent&#8217;s interest in the recorded net assets of Specialty Health and represents the cumulative net investment by the Parent in Specialty Health through the dates presented, inclusive of cumulative operating results. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial information included herein may not necessarily reflect the combined financial position, results of operations, changes in net Parent investment and cash flows of Specialty Health in the future or what they would have been had the Company been a separate, stand-alone entity during the periods presented. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:8.15pt;text-align:justify;text-indent:-8.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Combination</font></div><div style="padding-left:8.15pt;text-align:justify;text-indent:-8.15pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Combined Financial Statements are presented on a stand-alone basis and include the financial position, statements of income and cash flows of Specialty Health. All significant intercompany accounts and transactions within Specialty Health have been eliminated in the accompanying Combined Financial Statements. All intercompany balance receivables and payables between our Parent and Specialty Health are considered settled through net transfers to Parent.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Parent Investment</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specialty Health 's equity on the Combined Balance Sheets represents our Parent&#8217;s historical net investment in the Company, and is presented as &#34;net Parent investment&#34; in lieu of stockholders' equity given Specialty Health has no direct ownership relationship in the various entities comprising its operations. The Combined Statement of net Parent investment include corporate allocations, net cash transfers and other property transfers between our Parent and the Company. All transactions reflected in net Parent investment in the accompanying Combined Balance Sheet have been considered cash receipts and payments for purposes of the Combined Statement of Cash Flows and are reflected as financing activities in the accompanying Combined Statement of Cash Flows.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="background-color:#ffff00;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of net revenue during the reporting period. Significant estimates of the Company can include, among other things, valuation of intangible assets, valuation of goodwill, stock compensation assumptions, tax contingencies and legal liabilities. In addition, the Company also makes estimates in relation to revenue recognition under Accounting Standard Codification 606 (&#8220;ASC 606&#8221;) which are explained in more detail in &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; below. Actual results could differ from those estimates.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s revenues are derived from business in North America. The following tables disaggregate our revenue for the year ended December 31, 2022 by major service line, type of customer and timing of revenue recognition (in thousands)&#58;</font><font style="background-color:#ffff00;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.840%"><tr><td style="width:1.0%"></td><td style="width:84.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.067%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Major Service Lines</font></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-based</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,545&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASO</font></td><td colspan="2" style="background-color:#ccedff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,753&#160;</font></td><td style="background-color:#ccedff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenue</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,298&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Type of Customer</font></td><td colspan="3" style="background-color:#ccedff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-government</font></td><td colspan="2" style="background-color:#ccedff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,298&#160;</font></td><td style="background-color:#ccedff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenue</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,298&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ccedff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccedff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Timing of Revenue Recognition</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transferred at a point in time</font></td><td style="background-color:#ccedff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ccedff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ccedff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transferred over time</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,298&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenue</font></td><td style="background-color:#ccedff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ccedff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,298&#160;</font></td><td style="background-color:#ccedff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-right:11.8pt;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Per Member Per Month (&#8220;PMPM&#8221;) Revenue. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides its management services primarily through&#58; (i) risk-based contractual arrangements, where the Company assumes all or a substantial portion of the responsibility for the cost of providing treatment services in exchange for a fixed PMPM capitation payment, or (ii) ASO contractual arrangements, where the Company provides services such as utilization review, but does not assume full responsibility for the cost of the treatment services, in exchange for an administrative fee and, in some instances, shared savings. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk-based contracts have provision that include &#8220;profit share.&#8221; Under a contract with profit share provisions, if the cost to provide the care is below certain specified levels, the Company will &#8220;share&#8221; the cost savings with the customer at the percentages set forth in the contract.  In addition, certain contracts include provisions to provide the Company additional funding if the cost of care is above the specified levels.  Based on right to offset terms in certain contracts, the Company reflected accounts receivable net of the accrued liabilities related to the cost of the treatment services and profit share liability by customer.  If the customer was in a payable position the net liability was included within accrued liabilities.  </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For such risk-based contracts, the Company estimates cost of care using actuarial principles and assumptions that are consistently applied each reporting period and that recognizes the actuarial best estimate of the ultimate cost of care to be incurred, inclusive of a margin for adverse deviation. This approach is consistent with actuarial standards of practice that cost of care be adequate under moderately adverse conditions. For each reporting period, the Company compares key assumptions used to establish the reserves for claims and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance-based arrangements to actual experience. When actual experience differs from these assumptions, reserves for claims and performance-based arrangements are adjusted through current period net income.  </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operated under a risk-based contract with Centene that converted to an ASO contract (with fixed contractual terms not requiring actuarial estimates) as of January 1, 2022. The development of estimated cost of care for this contract in 2022, along with the reversal of the margin for adverse deviation, resulted in favorable changes in estimates to revenue of approximately $4.8 million that were recorded to the Company&#8217;s combined financial results in calendar 2022.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Almost all of the Specialty Health revenue is paid on a PMPM basis and is inclusive of revenue from the Company&#8217;s risk-based contracts and ASO contracts for services provided to its customers. PMPM contracts generally have a term of one year or longer. All managed care contracts have a single performance obligation that constitutes a series for the provision of managed healthcare services for a population of enrolled members for the duration of the contract. The transaction price for risk-based contracts or ASO contracts is entirely variable as it primarily includes PMPM fees associated with unspecified membership that fluctuates throughout the contract. In certain contracts, PMPM fees also include adjustments for things such as performance incentives, performance guarantees and risk shares. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally estimates the transaction price using an expected value methodology and amounts are only included in the net transaction price to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The majority of the Company&#8217;s net PMPM transaction price relates specifically to its efforts to transfer the service for a distinct increment of the series (e.g. day or month) and is recognized as revenue in the month in which members are entitled to service. The remaining transaction price is recognized over the contract period (or portion of the series to which it specifically relates) based upon estimated membership as a measure of progress.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance obligation on an activity-based contract is to stand ready to provide the activity or services purchased by the customer. The performance obligation represents a series for the duration of the arrangement. The reimbursement rate is fixed per the contract&#59; however, the level of activity is variable. A majority of the Company&#8217;s transaction price relates specifically to its efforts to transfer the service for a distinct increment of the series (e.g. day or month) and is recognized as revenue when the portion of the series for which it relates has been provided.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 606-10-50-13, the Company is required to include disclosure on its remaining performance obligations as of the end of the current reporting period. The majority of the Company&#8217;s contracts meet certain exemptions as defined in ASC 606-10-50-14 through 606-10-50-14A, including (i) performance obligation is part of a contract that has an original expected duration of one year or less&#59; (ii) the right to invoice practical expedient&#59; and (iii) variable consideration related to unsatisfied performance obligations that is allocated entirely to a wholly unsatisfied promise to transfer a distinct service that forms part of a single performance obligation, and the terms of that variable consideration relate specifically to our efforts to transfer the distinct service, or to a specific outcome from transferring the distinct service. For the Company&#8217;s contracts that pertain to these exemptions&#58; (i) the remaining performance obligations primarily relate to the provision of managed healthcare services to the customers&#8217; membership&#59; (ii) the estimated remaining duration of these performance obligations ranges from the remainder of the current calendar year to three years&#59; and (iii) variable consideration for these contracts as determined in accordance with the methodology above associated with unspecified membership that fluctuates throughout the contract.</font></div><div style="padding-right:11.8pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffff00;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable and Contract Assets</font></div><div style="margin-top:0.3pt;padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable and contract assets consisted of the following (in thousands)&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.840%"><tr><td style="width:1.0%"></td><td style="width:68.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.400%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">December 31, 2022</font></td></tr><tr><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</font></td><td style="background-color:#ccedff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ccedff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,439&#160;</font></td><td style="background-color:#ccedff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,657&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:0.05pt;padding-right:14.45pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the right to offset contractual provisions, the Company reflected accounts receivable net of accrued medical costs for treatment, customer settlements, and profit share as these are all included in the annual settlements with the respective customers. Accounts receivable, net for December 31, 2022, includes </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">gross accounts receivable of $83.9 million, which was offset by accrued medical costs for treatment of $41.6 million, profit share of $3.5 million and deferred revenue and other of $1.3 million.  </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounts receivable consists of amounts due from customers throughout the United States. Collateral is generally not required. A majority of the Company&#8217;s contracts have payment terms in the month of service, or within a few months thereafter. The timing of payments from customers from time to time generates contract assets or contract liabilities, however these amounts are immaterial.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounts receivable is net of an allowance for credit losses. The estimate of current expected credit losses on trade receivables considers historical credit loss information that is adjusted for current conditions and reasonable and supportable forecasts. Management elected to disaggregate trade receivables into business segments due to risk characteristics unique to each platform given the individual lines of business and market. Pooling was further disaggregated based on either geography or product type.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leveraged historical write offs over a defined lookback period in deriving a historical loss rate. The expected credit loss model further considers current conditions and reasonable and supportable forecasts through the use of an adjustment for current and projected macroeconomic factors. Management identified appropriate macroeconomic indicators based on tangible correlation to historical losses, giving consideration to the location and risks associated with the Company&#8217;s customers.</font></div><div style="margin-top:0.55pt;text-align:justify"><font><br></font></div><div style="padding-left:8.15pt;text-align:justify;text-indent:-8.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Concentration of Credit Risk</font></div><div style="margin-top:0.35pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable subjects the Company to a concentration of credit risk with third party payors that include health insurance companies, managed healthcare organizations and healthcare providers.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Significant Customers</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Customers exceeding ten percent of the combined Company&#8217;s net revenues</font></div><div style="padding-right:14.25pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The only customer that generated in excess of ten percent of net revenues for the year ended December 31, 2022 was the Centene. The Centene contract generated net revenue of $142.5 million and the current termination date for this contract is December 31, 2024.  </font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="margin-top:0.05pt;text-align:justify"><font><br></font></div><div style="margin-top:0.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Concentration of Business</font></div><div style="margin-top:0.05pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s contracts with customers typically have stated terms of one to three years, and in certain cases contain renewal provisions (at the customer&#8217;s option) for successive terms of between one and two years (unless terminated earlier). Substantially all of these contracts may be immediately terminated with cause and many of the Company&#8217;s contracts are terminable without cause by the customer or the Company either upon the giving of requisite notice and the passage of a specified period of time (typically between 30 and 180 days) or upon the occurrence of other specified events. </font></div><div style="padding-right:12.7pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-right:12.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</font></div><div style="margin-top:0.35pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations from January 1, 2022 through January 4, 2022 will be included in the consolidated federal income tax returns of Magellan, as well as certain separate state income tax returns of Magellan&#8217;s subsidiaries that are part of Specialty Health, and certain combined state income tax returns which included Magellan and its subsidiaries. Magellan became a wholly owned subsidiary of Centene as of January 4, 2022. After that date, the remaining 2022 operations of the Company will be included in the consolidated federal income tax return of Centene, as well as certain separate state income tax returns of Centene&#8217;s subsidiaries that are part of Specialty Health, and certain combined state income tax returns which included Centene and its subsidiaries and&#47;or Magellan and its subsidiaries. Income taxes as presented in the Combined Financial Statements attribute current and deferred income taxes of Magellan to the stand-alone financial statements of Specialty Health in a manner that is systematic, rational, and consistent with the asset and liability method prescribed by ASC 740. Accordingly, the income tax provision of Specialty Health was prepared following the separate return method. The separate return method applies ASC 740 to the stand-alone financial statements of each member of the consolidated group as if the group members were a separate taxpayer and a stand-alone enterprise. The calculation of our income taxes on a separate return basis requires a considerable amount of judgment and use of both estimates and allocations. As a result, actual transactions included in the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated financial statements of Magellan may not be included in the separate financial statements of Specialty Health. Similarly, the tax treatment of certain items reflected in the financial statements of Specialty Health may not be reflected in the consolidated financial statements of Magellan or the tax returns which include the Company&#8217;s operations. Further, the Company&#8217;s income tax results as presented in these financial statements may not necessarily be reflective of the result of the Company in the future. Management believes the assumptions underlying the allocation of income taxes in these Combined Financial Statements are reasonable. However, income tax results may not necessarily reflect the results had the Company been a separate, stand-alone entity during the periods presented. </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates income taxes for each of the jurisdictions in which it operates. This process involves determining both permanent and temporary differences resulting from differing treatment for tax and book purposes. Deferred tax assets and&#47;or liabilities are determined by multiplying the temporary differences between the financial reporting and tax reporting bases for assets and liabilities by the enacted tax rates expected to be in effect when such differences are recovered or settled. The Company then assesses the likelihood that the deferred tax assets will be recovered from the reversal of temporary differences, the implementation of feasible and prudent tax planning strategies, and future taxable income. To the extent the Company cannot conclude that recovery is more likely than not, it establishes a valuation allowance. The effect of a change in tax rates on deferred taxes is recognized in income in the period that includes the enactment date. Reversals of both valuation allowances and unrecognized tax benefits are recorded in the period they occur, typically as reductions to income tax expense.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All tax liabilities of the Company are paid by either Magellan or Centene. The Company does not record a tax liability owed to Magellan or Centene and such amount, if any, has been adjusted to net Parent investment. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Treasury activities, including activities related to the Company, are centralized by the Parent such that cash collections are generally distributed to the Parent and reflected as equity. Book overdrafts are reflected within accounts payable on the balance sheets. </font></div><div style="margin-top:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Fair Value Measurements</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has certain assets and liabilities that are required to be measured at fair value on a recurring basis. The carrying value of financial instruments, including accounts receivable and accounts payable, approximate their fair values due to their short-term maturities. The estimated fair values may not represent actual values of the financial instruments that could be realized as of the balance sheet date or that will be realized in the future. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Long-lived Assets</font></div><div style="margin-top:0.3pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets, including property and equipment and intangible assets to be held and used, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. We group and evaluate these long-lived assets for impairment at the lowest level at which individual cash flows can be identified. Impairment is determined by comparing the carrying value of these long-lived assets to management&#8217;s best estimate of the future undiscounted cash flows expected to result from the use of the assets and their eventual disposition. The cash flow projections used to make this assessment are consistent with the cash flow projections that management uses internally in making key decisions. In the event an impairment exists, a loss is recognized based on the amount by which the carrying value exceeds the fair value of the asset, which is generally determined by using quoted market prices or the discounted present value of expected future cash flows.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:8.15pt;text-align:justify;text-indent:-8.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Property and Equipment</font></div><div style="margin-top:0.3pt;text-align:justify"><font><br></font></div><div style="padding-right:15.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is stated at cost, except for assets that have been impaired, for which the carrying amount has been reduced to estimated fair value. Expenditures for renewals and improvements are capitalized to the property accounts. Replacements and maintenance and repairs that do not improve or extend the life of the respective assets are expensed as incurred. The Company capitalizes costs incurred to develop internal-use software during the application development stage. Capitalization of software </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-right:15.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development costs occurs after the preliminary project stage is complete, management authorizes the project, and it is probable that the project will be completed and the software will be used for the function intended. Depreciation is provided on a straight-line basis over the estimated useful lives of the assets, which is generally three to fifteen years for equipment and three to five years for capitalized internal-use software. The net capitalized internal use software as of December 31, 2022 was $6.1 million. </font></div><div style="padding-right:15.05pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-top:0.45pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $4.7 million for the year ended December 31, 2022. Included in depreciation expense for the year ended December 31, 2022 was $4.0 million related to capitalized internal-use software.  </font></div><div style="margin-top:6.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net, consisted of the following at December 31, 2022 (in thousands)&#58;</font></div><div style="margin-bottom:0.05pt;margin-top:0.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">     </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.840%"><tr><td style="width:1.0%"></td><td style="width:84.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,051&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized internal-use software</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,109&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccedff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccedff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,160&#160;</font></td><td style="background-color:#ccedff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,151)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td style="background-color:#ccedff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ccedff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,009&#160;</font></td><td style="background-color:#ccedff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">     </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Goodwill</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to test its goodwill for impairment on at least an annual basis. The Company has selected October 1 as the date of its annual impairment test. The goodwill impairment test is a two-step process that requires management to make judgments in determining what assumptions to use in the calculation. The first step of the process consists of estimating the fair value of the reporting unit based on various valuation techniques, with the primary technique being a discounted cash flow analysis, which requires the input of various assumptions with respect to revenues, operating margins, growth rates and discount rates. The estimated fair value for the reporting unit is compared to the carrying value of the reporting unit, which includes goodwill. If the estimated fair value is less than the carrying value, a second step is performed to compute the amount of the impairment by determining an &#8220;implied fair value&#8221; of goodwill. The determination of a reporting unit&#8217;s &#8220;implied fair value&#8221; of goodwill requires the Company to allocate the estimated fair value of the reporting unit to the assets and liabilities of the reporting unit. Any unallocated fair value represents the &#8220;implied fair value&#8221; of goodwill, which is compared to its corresponding carrying value.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is tested for impairment at a level referred to as a reporting unit. The Company has one reporting unit as of December 31, 2022.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the reporting unit was determined using a discounted cash flow method. This method involves estimating the present value of estimated future cash flows utilizing a risk adjusted discount rate. Key assumptions for this method include cash flow projections, terminal growth rates and discount rates.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the reporting unit goodwill is not impaired during 2022, reporting unit goodwill is at risk of future impairment in the event of significant unfavorable changes in the Company&#8217;s forecasted future results and cash flows. In addition, market factors utilized in the impairment analysis, including long-term growth rates or discount rates, could negatively impact the fair value of our reporting unit. For testing purposes, management's best estimates of the expected future results are the primary driver in determining the fair value. Fair value determinations require considerable judgment and are sensitive to changes in underlying assumptions and factors. As a result, there can be no assurance that the estimates and assumptions made for purposes of the annual goodwill test will prove to be an accurate prediction of the future.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Examples of events or circumstances that could reasonably be expected to negatively affect the underlying key assumptions and ultimately impact the estimated fair value of our reporting units may include such items as&#58; (i) a decrease in expected future cash flows, specifically, a decrease in membership or rates or customer attrition and increase in costs that could significantly impact our immediate and long-range results, unfavorable working capital changes and an inability to successfully achieve our cost savings targets, (ii) adverse changes in macroeconomic conditions or an economic recovery that significantly differs from our assumptions in timing and&#47;or degree (such as a recession)&#59; and (iii) volatility in the equity and debt markets or other country specific factors which could result in a higher weighted average cost of capital.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on known facts and circumstances, we evaluate and consider recent events and uncertain items, as well as related potential implications, as part of our annual assessment and incorporate into the analyses as appropriate. These facts and circumstances are subject to change and may impact future analyses.<br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While historical performance and current expectations have resulted in fair values of our reporting unit in excess of carrying values, if our assumptions are not realized, it is possible that an impairment charge may need to be recorded in the future.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the carrying amount of goodwill for the year ended December 31, 2022 is reflected in the table below (in thousands)&#58;</font></div><div style="padding-left:318.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:80%">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.840%"><tr><td style="width:1.0%"></td><td style="width:84.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning of period</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,214&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and measurement period adjustments</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,214&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Intangible Assets</font></div><div style="margin-top:0.3pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews other intangible assets for impairment when events or changes in circumstances occur which may potentially impact the estimated useful life of the intangible assets.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of intangible assets at December 31, 2022, and the estimated useful lives for such assets (in thousands, except useful lives)&#58;</font></div><div><font><br></font></div><div style="margin-bottom:0.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">     </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.351%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.959%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.959%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.504%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.959%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.959%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.674%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.959%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Original Useful Life</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Weighted Avg Remaining</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Useful Life</font></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Net Carrying</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Amount</font></div></td></tr><tr><td colspan="3" style="background-color:#ccedff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer agreements and lists</font></td><td colspan="3" style="background-color:#ccedff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccedff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 Years</font></td><td colspan="3" style="background-color:#ccedff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccedff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 Years</font></td><td colspan="3" style="background-color:#ccedff;padding:0 1pt"></td><td style="background-color:#ccedff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ccedff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,900&#160;</font></td><td style="background-color:#ccedff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccedff;padding:0 1pt"></td><td style="background-color:#ccedff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ccedff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,900)</font></td><td style="background-color:#ccedff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccedff;padding:0 1pt"></td><td style="background-color:#ccedff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ccedff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ccedff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider networks</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 Years</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 Years</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,394&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,124)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccedff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccedff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccedff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccedff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccedff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccedff;padding:0 1pt"></td><td style="background-color:#ccedff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ccedff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,294&#160;</font></td><td style="background-color:#ccedff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccedff;padding:0 1pt"></td><td style="background-color:#ccedff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ccedff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,024)</font></td><td style="background-color:#ccedff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccedff;padding:0 1pt"></td><td style="background-color:#ccedff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ccedff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</font></td><td style="background-color:#ccedff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:0.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">     </font></div><div style="margin-top:0.05pt;padding-right:12.7pt;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense was $0.1 million for the year ended December 31, 2022. The Company estimates amortization expense will be $87.8 thousand, $87.8 thousand, $87.8 thousand and $7.3 thousand for the years ending December 31, 2023, 2024, 2025, and 2026, respectively.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accrued Liabilities</font></div><div style="margin-top:0.05pt;padding-right:12.7pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the individual current liability that exceeded five percent of total current liabilities related to accrued payroll and other employee related liabilities of $13.6 million.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Stock Compensation</font></div><div style="margin-top:0.3pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has no stock-based compensation plans, however certain employees of the Company participate in Centene&#8217;s stock-based compensation plans, which provide for the grants of restricted stock units (&#8220;RSUs&#8221;). </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock compensation expense is recognized at grant date fair value over the period during which an employee is required to provide service in exchange for the award.  Excess tax benefits related to stock compensation are presented as a cash inflow from operating activities.  Forfeitures are accounted for when they occur.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock compensation expense includes compensation for employees specifically dedicated to the Company, as well as an allocation of corporate stock compensation expense based on a value-added base approach.  Stock compensation expense was $0.7 million for the year ended December 31, 2022. </font></div><div style="margin-top:0.05pt;padding-right:12.75pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-top:0.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3. Benefit Plans</font></div><div style="margin-top:0.3pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have a defined contribution retirement plan, however certain employees of the Company participate in the Parent's defined contribution retirement plan (the &#8220;401(k) Plan&#8221;). Employee participants can elect to contribute up to 75 percent of their compensation, subject to Internal Revenue Service (&#8220;IRS&#8221;) deferral limitations. The Company makes contributions to the 401(k) Plan based on employee compensation and contributions. The Company matches 50 percent of each employee&#8217;s contribution up to 6 percent of their annual compensation. The Company recognized $1.4 million of expense for the year ended December 31, 2022 for matching contributions to the 401(k) Plan.</font></div><div style="padding-right:12.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div><div style="padding-right:12.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4. Income Tax </font></div><div style="margin-top:0.3pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Income Tax Expense</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of income tax expense (benefit) in continuing operations for the year ended December 31, 2022 were as follows (in thousands)&#58;</font></div><div style="margin-top:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.840%"><tr><td style="width:1.0%"></td><td style="width:84.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current income tax&#58;</font></td><td colspan="3" style="background-color:#ccedff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,953&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</font></td><td colspan="2" style="background-color:#ccedff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,150&#160;</font></td><td style="background-color:#ccedff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,103&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes (benefits)&#58;</font></td><td colspan="3" style="background-color:#ccedff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(777)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</font></td><td colspan="2" style="background-color:#ccedff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(198)</font></td><td style="background-color:#ccedff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(975)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax expense</font></td><td style="background-color:#ccedff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ccedff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,128&#160;</font></td><td style="background-color:#ccedff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="padding-right:15.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total income tax expense in continuing operations for the year ended December 31, 2022 was different from the amount computed using the statutory federal income tax rate in effect for the year for the following reasons (in thousands)&#58;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.840%"><tr><td style="width:1.0%"></td><td style="width:84.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense at federal statutory rate</font></td><td style="background-color:#ccedff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ccedff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,052&#160;</font></td><td style="background-color:#ccedff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal income tax benefit</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,081&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</font></td><td colspan="2" style="background-color:#ccedff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</font></td><td style="background-color:#ccedff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax expense</font></td><td style="background-color:#ccedff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ccedff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,128&#160;</font></td><td style="background-color:#ccedff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Deferred Income Taxes</font></div><div style="margin-top:0.3pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant components of deferred tax assets and liabilities at December 31, 2022 was as follows (in thousands)&#58;</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.513%"><tr><td style="width:1.0%"></td><td style="width:80.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.035%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.058%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets&#58;</font></td><td colspan="3" style="background-color:#ccedff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccedff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued compensation</font></td><td colspan="3" style="background-color:#ccedff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccedff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">773&#160;</font></td><td style="background-color:#ccedff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-deductible accrued liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other deferred tax assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</font></td><td colspan="3" style="background-color:#ccedff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccedff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,147&#160;</font></td><td style="background-color:#ccedff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowances</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets after valuation allowances</font></td><td colspan="3" style="background-color:#ccedff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccedff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,147&#160;</font></td><td style="background-color:#ccedff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</font></td><td colspan="3" style="background-color:#ccedff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccedff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(696)</font></td><td style="background-color:#ccedff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(536)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaids</font></td><td colspan="3" style="background-color:#ccedff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccedff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142)</font></td><td style="background-color:#ccedff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other deferred tax liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccedff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</font></td><td colspan="3" style="background-color:#ccedff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccedff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,375)</font></td><td style="background-color:#ccedff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(228)</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-right:11.7pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the stand-alone approach used to determine the deferred income taxes, the Company has no net operating losses to reduce federal, state, or local taxable income in 2022 and subsequent years. &#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Uncertain Tax Positions</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Magellan continually performs a comprehensive review of its tax positions and accrues amounts for tax contingencies related to uncertain tax positions. Based upon these reviews, no uncertain tax positions were related to the Company and no uncertain tax positions were identified on a stand-alone basis. &#160;</font></div><div style="padding-right:11.7pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5. Commitments and Contingencies </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-right:12.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Regulatory Issues</font></div><div style="padding-right:12.6pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The managed healthcare industry is subject to numerous laws and regulations. The subjects of such laws and regulations cover, but are not limited to, matters such as licensure, accreditation, government healthcare program participation requirements, information privacy and security, reimbursement for patient services, and Medicare and Medicaid fraud and abuse. Over the past several years, government activity has increased with respect to investigations and&#47;or allegations concerning possible violations of fraud and abuse and false claims statutes and&#47;or regulations by healthcare organizations and insurers. Entities that are found to have violated these laws and regulations may be excluded from participating in government healthcare programs, subjected to fines or penalties or required to repay amounts received from the government for previously billed patient services. Compliance with such laws and regulations can be subject to future government review and interpretation, as well as regulatory actions unknown or unasserted at this time.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, regulators of the Company may exercise certain discretionary rights under regulations including increasing their supervision of such entities, requiring additional restricted cash or other security or seizing or otherwise taking control of the assets and operations of the Company.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-right:12.2pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal</font></div><div style="margin-top:0.35pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s operating activities entail significant risks of liability. From time to time, the Company is subject to various actions and claims arising from the acts or omissions of its employees, network providers or other parties. In the normal course of business, the Company receives reports relating to deaths and other serious incidents involving patients whose care is being managed by the Company. Such incidents occasionally give </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rise to malpractice, professional negligence and other related actions and claims against the Company or its network providers. Many of these actions and claims received by the Company seek substantial damages and therefore require the Company to incur significant fees and costs related to their defense.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also subject to or party to certain class actions and other litigation and claims relating to its operations or business practices, including network provider reimbursement, employment practices and privacy and data protection. The Company has recorded reserves that, in the opinion of management, are adequate to cover litigation, claims or assessments that have been or may be asserted against the Company, and for which the outcome is probable and reasonably estimable. Management believes that the resolution of such litigation and claims will not have a material adverse effect on the Company&#8217;s financial condition or results of operations&#59; however, there can be no assurance in this regard.</font></div><div style="padding-right:14.25pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6. Related Party Transactions</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, the Company has been managed and operated in the normal course of business consistent with other affiliates of the Parent. Accordingly, certain shared costs have been allocated to Specialty Health and reflected as expenses in the Combined Financial Statements. Management considers the allocation methodologies used to be reasonable and appropriate reflections of the historical Parent expenses attributable to Specialty Health for purposes of the stand-alone financial statements. However, the expenses reflected in the Combined Financial Statements may not be indicative of the actual expenses that would have been incurred during the periods presented if Specialty Health historically operated as a separate, stand-alone entity. In addition, the expenses reflected in the Combined Financial Statements may not be indicative of related expenses that will be incurred in the future by Specialty Health.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Centralized Treasury</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Treasury activities, including activities related to the Company, are centralized by the Parent such that net cash collections and disbursements are generally distributed to the Parent and reflected as net Parent investment.  Settlement of Specialty Health's transactions with the Parent are considered to be financing transactions, which are presented as Net Transfers to Parent in the accompanying statement of cash flows.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">General Corporate Overhead &#47; Costs</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Combined Statements of Income include costs related to employees within shared services centers that were fully dedicated to the Company based on identification of cost centers specific to the Company&#8217;s operations.  These costs are primarily related to administrative and other corporate support services.   The Combined Balance Sheet includes accruals of $15.1 million at December 31, 2022 related to the costs of such employees, which is included in accounts payable, accrued liabilities and other long-term liabilities.  </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, certain of Magellan&#8217;s corporate overhead costs were allocated to the Company using Magellan&#8217;s allocation methodologies described in note 2.  A portion of these allocated costs include expenses related to employees that were not considered to be fully dedicated to the Company.  As these corporate overhead expenses are considered to be intercompany transactions, the allocated costs are deemed to be settled when incurred and are included in the net parent investment on the combined balance sheets.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total costs associated with these charges, including the costs of both the fully dedicated employees through shared services centers and the allocated costs from Magellan to the Company described above, were of $182.1 million for the year ended December 31, 2022, which is included in the direct service costs and other operating expenses on the Combined Statements of Income.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Amounts due from Affiliates, net</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2022, the Company provided carve-out management services for areas of specialty healthcare to various Centene health plans.  Included within 2022 revenues is $142.5 million for services provided to Centene.  At December 31, 2022, the Company has a net receivable from Centene of $13.0 million which is reflected as amounts due from affiliates on the combined balance sheet.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7. Subsequent Events</font></div><div style="margin-top:0.1pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 17, 2022, Magellan Health, Inc. and Magellan Healthcare, Inc. executed a definitive agreement to sell Magellan&#8217;s Specialty Health business to Evolent Health, Inc. (&#8220;Evolent&#8221;) (collectively the &#8220;Sale&#8221;).   Given MPT and MLIC no longer have any specialty business, the only legal entities included in the Sale are NIA and its non-dissolved subsidiaries. The Sale closed on January 20, 2023, resulting in NIA becoming a wholly owned subsidiary of Evolent.  In addition to the Sale, Evolent and Centene are expanding Centene&#8217;s relationship with NIA, now part of Evolent, and extending NIA&#8217;s contracts with Centene through 2027. </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated events of which it is aware occurring after December 31, 2022 through October 13, 2023, the date the financial statements were available to be issued.  The Company did not have any material recognizable subsequent events during this period other than the item described above.</font></div><div style="margin-top:4.6pt;padding-right:17.25pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><br></font></div><div style="margin-top:0.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>4
<FILENAME>exhibit992niaproforma.htm
<DESCRIPTION>EX-99.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i07edbe7d82594d98894c29eab50ef89c_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Exhibit 99.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited pro forma condensed combined financial statements have been prepared based on the historical consolidated financial statements of Evolent Health, Inc. (&#8220;Evolent&#8221;, &#8220;we&#8221;, &#8220;the Company&#8221;) to give effect to the following transaction (the &#8220;Transaction&#8221;)&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 20, 2023, Evolent and Evolent Health LLC (&#8220;EVH LLC&#8221; and, together with Evolent, the &#8220;Evolent Entities&#8221;), completed its acquisition of National Imaging Associates Inc. (&#8220;NIA&#8221;), including all of the issued and outstanding shares of capital stock of NIA as well as certain assets held by Magellan Health, Inc. (&#8220;Magellan Parent&#8221;) and certain of its subsidiaries that were used in the Magellan Specialty Health Division.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of and as set forth in the Purchase Agreement, the Evolent Entities paid $387.8 million of cash consideration (inclusive of certain post-closing adjustments) and issued 8,474,576 shares of Evolent&#8217;s Class A common stock (&#8220;Class A Shares&#8221;), fair valued at $261.3 million as of January 20, 2023 (together the &#8220;Transaction Consideration&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Transaction Consideration, Magellan Parent shall be eligible to receive, subject to the satisfaction of certain metrics set forth in the Purchase Agreement, including those related to the achievement of certain operating results during calendar year 2023 (the &#8220;Earnout Period&#8221;), or upon the occurrence of certain events, additional consideration of up to $150.0 million payable in cash and Class A Shares valued at a price equal to the volume weighted average closing price of such Class A Shares on the New York Stock Exchange for 20 trading days ending on the trading day that is immediately prior to two (2) business days prior to the date such payment is required to be made pursuant to the Purchase Agreement (the &#8220;Earnout Consideration&#8221;). Subject to the conditions applicable thereto, up to 50% of the Earnout Consideration may be paid in Class A Shares&#59; provided, however, the Evolent Entities may, in their discretion, increase the portion of the Earnout Consideration payable in cash and correspondingly decrease the portion of the Earnout Consideration payable in Class A Shares. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ares Capital Management LLC and Ares Capital Corporation (together &#8220;Ares&#8221;) provided Evolent with secured debt financing in the form of (i) additional commitments under the Company&#8217;s existing asset-based revolving credit facility in an aggregate principal amount equal to $25.0 million, and (ii) additional commitments under the existing initial term loan facility in an aggregate principal amount equal to $240.0 million (clauses (i) and (ii), the &#8220;Acquisition Facilities&#8221;), and certain amendments to the Company&#8217;s existing credit agreement have been made. Additionally, Ares  purchased from Evolent an aggregate $175.0 million initial liquidation preference of a newly issued, perpetual series of Evolent&#8217;s convertible preferred stock. The purchase price of the convertible preferred stock was equal to 96% of its initial liquidation preference. Each holder of convertible preferred stock has the right, at its option, to convert its shares of convertible preferred stock into Class A Shares at an initial conversion price per share of $40.00 of current liquidation preference per share, subject to customary anti-dilution adjustments. The proceeds of borrowings under the Acquisition Facilities and from the sale of the preferred stock were used to fund the Transaction Consideration.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pro forma combined statement of income have been prepared to reflect the transaction accounting adjustments to Evolent&#8217;s historical consolidated financial information to account for the Transaction. The unaudited pro forma combined statement of income for the nine months ended September 30, 2023 and the year ended December 31, 2022 give effect to the Transaction, in each case, as if it had been completed on January 1, 2022.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pro forma financial statements are provided for illustrative purposes only and are not intended to represent what Evolent&#8217;s financial position or results of operations would have been had the Transaction been consummated on the assumed dates, nor do they purport to project the future operating results or the financial position of the combined company following the transaction. The actual financial position and results of operations of Evolent after consummation of the Transaction may differ significantly from the pro forma amounts reflected herein due to a variety of factors. Assumptions and estimates underlying the pro forma adjustments are described in the accompanying notes, which should be read in conjunction with the pro forma financial statements. In Evolent&#8217;s opinion, all adjustments that are necessary to present fairly the pro forma information have been made. The pro </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt;text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">forma financial statements do not include any pro forma adjustments to reflect certain expected financial benefits of the Transaction, such as cost synergies or revenue synergies, or the anticipated costs to achieve those benefits.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pro forma financial statements should be read in conjunction with the following&#58; </font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1)&#160;&#160;&#160;&#160;Evolent&#8217;s audited consolidated financial statements and related notes included in Evolent&#8217;s annual report on Form 10-K for the year ended December 31, 2022. </font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2)&#160;&#160;&#160;&#160;Evolent&#8217;s unaudited consolidated financial statements and related notes included in Evolent&#8217;s quarterly report on Form 10-Q for the quarterly period ended September 30, 2023. </font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3)&#160;&#160;&#160;&#160;Historical audited combined financial statements and related notes of Magellan Specialty Health as of December 31, 2022 and for the year ended December 31, 2022, included as Exhibit 99.1 to Evolent&#8217;s current report on Form 8-K to which these unaudited pro forma combined financial statements are attached. </font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:8pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">UNAUDITED PRO FORMA COMBINED STATEMENT OF INCOME</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands, except for per share amounts)</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#221e20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#221e20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Evolent Health, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#221e20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Magellan Specialty Health</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#221e20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Transaction Accounting Adjustments</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#221e20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Notes</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#221e20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Pro Forma Combined</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Revenue</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,407,841</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">11,425</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,419,266</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Expenses</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cost of revenue</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,048,998</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">5,593</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,054,591</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Selling, general and administrative expenses</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">276,682</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,181</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">278,863</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Depreciation and amortization expenses</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">93,813</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">149</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,403</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(a) (b)</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">95,365</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Right-of-use assets impairment</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">24,065</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">24,065</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Loss on disposal of assets</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,097</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,097</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Change in fair value of contingent consideration</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">12,047</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">12,047</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total operating expenses</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,457,702</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">7,923</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,403</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,467,028</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Operating income (loss)</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(49,861)</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3,502</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(1,403)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(47,762)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Interest income</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,735</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,735</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Interest expense</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(41,967)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(5,169)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(c)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(47,136)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Gain from equity method investees</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,262</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,262</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Change in tax receivable agreement liability</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(66,184)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">66,184</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(d)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Other expense, net</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(323)</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(323)</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Income (loss) before income taxes</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(154,338)</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3,502</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">59,612</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(91,224)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Provision for (benefit from) income taxes</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(74,709)</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">54,418</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(e)</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(20,291)</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Income (loss) before preferred dividends and accretion of Series A Preferred Stock</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(79,629)</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3,502</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">5,194</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(70,933)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Dividends and accretion of Series A Preferred Stock</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(21,236)</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(2,682)</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(f)&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(23,918)</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Net income (loss) attributable to common shareholders of Evolent Health, Inc.</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(100,865)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3,502</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,512</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(94,851)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Loss per common share</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Basic and diluted loss per share attributable to common shareholders</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$ (0.91)</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(g)</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(0.85)</font></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Weighted-Average common shares outstanding</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Basic and diluted</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">110,464</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">937</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(g)</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">111,401</font></td></tr></table></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:8pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">UNAUDITED PRO FORMA COMBINED STATEMENT OF INCOME</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FOR THE YEAR ENDED DECEMBER 31, 2022 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands, except for per share amounts)</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.124%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.127%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#221e20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#221e20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Evolent Health, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#221e20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Magellan Specialty Health</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#221e20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Transaction Accounting Adjustments</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#221e20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Notes</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#221e20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Pro Forma Combined</font></td></tr><tr><td colspan="3" style="background-color:#ccecff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Revenues</font></td><td style="background-color:#ccecff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="background-color:#ccecff;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,352,013</font></td><td style="background-color:#ccecff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="background-color:#ccecff;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">255,298</font></td><td style="background-color:#ccecff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="background-color:#ccecff;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#ccecff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ccecff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="background-color:#ccecff;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,607,311</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Expenses</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccecff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cost of revenue</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,035,429</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">134,738</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,170,167</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Selling, general and administrative expenses</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">269,269</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">58,305</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">327,574</font></td></tr><tr><td colspan="3" style="background-color:#ccecff;padding:2px 1pt 2px 11.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Depreciation and amortization expenses</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">67,195</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">4,866</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">32,381</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(a) (b)</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">104,442</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Change in fair value of contingent consideration </font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(23,522)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(23,522)</font></td></tr><tr><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total operating expenses </font></div></td><td colspan="3" style="background-color:#ccecff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,348,371</font></td><td colspan="3" style="background-color:#ccecff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">197,909</font></td><td colspan="3" style="background-color:#ccecff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">32,381</font></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,578,661</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Operating income (loss) </font></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3,642</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">57,389</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(32,381)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right;text-indent:20pt"><font><br></font></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">28,650</font></td></tr><tr><td colspan="3" style="background-color:#ccecff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Interest income</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,369</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right;text-indent:20pt"><font><br></font></div></td><td colspan="3" style="background-color:#ccecff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,369</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Interest expense</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(15,572)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(49,714)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(c)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(65,286)</font></td></tr><tr><td colspan="3" style="background-color:#ccecff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Gain from equity method investees</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">4,569</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">4,569</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Loss on extinguishment&#47;repayment of debt</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(10,192)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(10,192)</font></td></tr><tr><td colspan="3" style="background-color:#ccecff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Change in tax receivable agreement liability</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(45,950)</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(66,184)</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(d)</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(112,134)</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Other income, net</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">57</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">57</font></td></tr><tr><td colspan="3" style="background-color:#ccecff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Income (loss) before income taxes</font></td><td colspan="3" style="background-color:#ccecff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(62,077)</font></td><td colspan="3" style="background-color:#ccecff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">57,389</font></td><td colspan="3" style="background-color:#ccecff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(148,279)</font></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(152,967)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Provision for (benefit from) income taxes</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(43,376)</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">15,128</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(79,570)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(e)</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(107,818)</font></td></tr><tr><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before preferred dividends and accretion of Series A Preferred Stock</font></div></td><td colspan="3" style="background-color:#ccecff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(18,701)</font></td><td colspan="3" style="background-color:#ccecff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">42,261</font></td><td colspan="3" style="background-color:#ccecff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(68,709)</font></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(45,149)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Dividends and accretion of Series A Preferred Stock</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(31,257)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(f)</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 3.77pt 2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(31,257)</font></td></tr><tr><td colspan="3" style="background-color:#ccecff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Net income (loss) attributable to shareholders of Evolent Health, Inc.</font></td><td style="background-color:#ccecff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="background-color:#ccecff;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(18,701)</font></td><td style="background-color:#ccecff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="background-color:#ccecff;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">42,261</font></td><td style="background-color:#ccecff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="background-color:#ccecff;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(99,966)</font></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td style="background-color:#ccecff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="background-color:#ccecff;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(76,406)</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccecff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Loss per common share</font></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Basic and diluted loss per share attributable to common shareholders</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(0.20)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(g)</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(0.75)</font></td></tr><tr><td colspan="3" style="background-color:#ccecff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Weighted-average common shares outstanding</font></td><td colspan="3" style="background-color:#ccecff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Basic and diluted</font></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">93,699</font></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right;text-indent:20pt"><font><br></font></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">8,475</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(g)</font></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">102,174</font></td></tr></table></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NOTES TO THE UNAUDITED PRO FORMA COMBINED FINANCIAL STATEMENTS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Note 1. Basis of Presentation</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying pro forma financial statements were prepared in accordance with Article 11 of Regulation S-X, as amended, including pursuant to SEC Final Rule, Amendments to Financial Disclosures about Acquired and Disposed Businesses, release number 33-10786 dated May 20, 2020 (&#8220;Article 11&#8221;), using the acquisition method of accounting under U.S. GAAP. Transaction accounting adjustments have been made to show the effects of the Transaction on the combined historical financial statements of Evolent Health, Inc. and Magellan Specialty Health. A reclassification adjustment has been made to the historical presentation of Magellan Specialty to conform to the financial statement presentation of Evolent Health, Inc. for the unaudited pro forma condensed combined financial information as noted below. Refer to Note 3 &#8211; Reclassification of Magellan Specialty Health&#8217;s Combined Statement of Income for further details on the reclassification adjustment.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2. Acquisition of Magellan Specialty Health </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 20, 2023, Evolent and Evolent Health LLC (&#8220;EVH LLC&#8221; and, together with Evolent, the &#8220;Evolent Entities&#8221;), completed its acquisition of National Imaging Associated Inc. (&#8220;NIA&#8221;), including all of the issued and outstanding shares of capital stock of NIA as well as certain assets held by Magellan Health, Inc. (&#8220;Magellan Parent&#8221;) and certain of its subsidiaries that were used in the Magellan Specialty Health Division.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of and as set forth in the Purchase Agreement, the Evolent Entities paid $387.8 million as cash consideration (inclusive of certain post-closing adjustments) and issued 8,474,576 shares Evolent&#8217;s Class A common stock (&#8220;Class A Shares&#8221;), fair valued at $261.3 million as of January 20, 2023.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Transaction Consideration, Magellan Parent is eligible to receive, subject to the satisfaction of certain metrics set forth in the Purchase Agreement, including those related to the achievement of certain operating results during calendar year 2023 (the &#8220;Earnout Period&#8221;), or upon the occurrence of certain events, additional consideration of up to $150.0 million payable in cash and Class A Shares valued at a price equal to the volume weighted average closing price of such Class A Shares on the New York Stock Exchange for 20 trading days ending on the trading day that is immediately prior to two (2) business days prior to the date such payment is required to be made pursuant to the Purchase Agreement (the &#8220;Earnout Consideration&#8221;). Subject to the conditions applicable thereto, up to 50% of the Earnout Consideration may be paid in Class A Shares&#59; provided, however, the Evolent Entities may, in their discretion, increase the portion of the Earnout Consideration payable in cash and correspondingly decrease the portion of the Earnout Consideration payable in Class A Shares. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ares Capital Management LLC and Ares Capital Corporation have provided Evolent with secured debt financing in the form of Acquisition Facilities, and certain amendments to the Company&#8217;s existing credit agreement have been made. Additionally, Evolent entered into a preferred stock financing commitment letter with Ares where Ares has purchased from Evolent an aggregate $175.0 million initial liquidation preference of a newly issued, perpetual series of Evolent&#8217;s convertible preferred stock. The purchase price of the convertible preferred stock was equal to 96% of its initial liquidation preference. Each holder of convertible preferred stock has the right, at its option, to convert its shares of convertible preferred stock into Class A Shares at an initial conversion price per share of $40.00 of current liquidation preference per share, subject to customary anti-dilution adjustments. The proceeds of borrowings and preferred stock were used to fund the Transaction Consideration. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3. Reclassification of Magellan Specialty Health&#8217;s Combined Statement of Income</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reclassification adjustment was made to Magellan Specialty Health&#8217;s combined statement of income for the year ended December 31, 2022, to conform to the classification and presentation of the Company&#8217;s consolidated statement of operations. Such reclassification adjustment included reclassifying $193.0 million of direct service </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt;text-align:right"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs and other operating expenses into cost of revenue and selling, general and administrative expenses for $134.7 million and $58.3 million, respectively.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4. Pro Forma Adjustments</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments included in the column labeled &#8220;Transaction Accounting Adjustments&#8221; in the unaudited combined pro forma statement of income is as follows (all amounts in thousands unless otherwise noted)&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Reflects the removal of historical depreciation expense of $37 thousand and $4.7 million for the nine months ended September 30, 2023 and year ended December 31, 2022, respectively. Depreciation expense of $4.0 million was related to capitalized software and is replaced by amortization of a developed technology intangible asset for the year ended December 31, 2022. </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;To remove historical amortization of the intangible assets and the recording of the pro forma amortization expense related to the identifiable intangible assets resulting from a fair valuation as if the acquisition occurred on January 1, 2022 (in thousands).</font></div><div style="margin-bottom:0.08pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.613%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">For the Nine Months Ended September 30, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">For the Year Ended December 31, 2022</font></td></tr><tr><td colspan="3" style="background-color:#ccecff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Removal of historical amortization expense</font></td><td style="background-color:#ccecff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="background-color:#ccecff;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(112)</font></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td style="background-color:#ccecff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="background-color:#ccecff;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(139)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pro forma amortization expense</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,552</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">37,247</font></td></tr><tr><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:30pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pro forma adjustment for amortization expense</font></div></td><td style="background-color:#ccecff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="background-color:#ccecff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,440</font></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td style="background-color:#ccecff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="background-color:#ccecff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">37,108</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This adjustment represents the amortization of the following intangible assets acquired along with the values and useful lives as outlined below (in thousands).</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Customer relationships (useful life 15 years)</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div></td><td style="background-color:#ccecff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="background-color:#ccecff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">345,100</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Technology (useful life 5 years)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">50,700</font></td></tr><tr><td colspan="3" style="background-color:#ccecff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Corporate trade name (useful life 2 years)</font></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="3" style="background-color:#ccecff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">8,200</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Total identifiable intangible assets acquired </font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">404,000</font></td></tr></table></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;To remove historical interest expense on debt and its related amortization of deferred financing costs on its Ares credit agreement and record pro forma interest expense and amortization of related debt issuance costs (in thousands).</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">For the Nine Months Ended September 30, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">For the Year Ended December 31, 2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Removal of historical interest expense</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(36,641)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(7,918)</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pro forma interest expense</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">41,747</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">55,511</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 39.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pro forma adjustment</font></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">5,106</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">47,593</font></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Removal of historical amortization of deferred financing costs</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(1,809)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(364)</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pro forma amortization of deferred financing costs</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,872</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,485</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 39.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pro forma adjustment</font></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">63</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,121</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total pro forma adjustment</font></td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">5,169</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">49,714</font></td></tr></table></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense was calculated to be 11.5% (adjusted Term SOFR Rate of 5.3% as of September 25, 2023 plus 6.2%) and 9.5% (adjusted Term SOFR Rate of 5.3% as of September 25, 2023 plus 4.2%) for the term loan and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt;text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revolver loan, respectively. Assuming an increase in interest rates on the existing and incremental long-term debt of 1&#47;8%, pro forma interest expense would increase by $0.5 million and $0.6 million for the nine months ended September 30, 2023 and year ended December 31, 2022, respectively.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Reflects the adjustment to the amount that the Company has to pay to certain investors with whom it entered into the Tax Receivables Agreement (the &#8220;TRA&#8221;). The TRA provides for the payment by the Company to these investors of 85% of the amount of the tax benefits, if any, that the Company is deemed to realize as a result of increases in tax basis related to exchanges of Class B common units as well as tax benefits attributable to the future utilization of pre-IPO NOLs. For purposes of presentation in the pro forma statement of income, the change in TRA of $66.2 million was removed for the nine months ending September 30, 2023 and the full $112.1 million charge was recorded for the year ended December 31, 2022.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;Reflects an estimated income tax impact of the pro forma adjustments from the acquisition at a forecasted blended statutory tax rate of 26%. The pro forma income tax adjustments included in the pro forma statement of income for the periods ended September 30, 2023, and December 31, 2022 reflect the income tax effects of the transaction accounting adjustments presented, in addition to adjustments to remove the valuation allowance as of January 1, 2022. This resulted in the reversal of the release of Evolent&#8217;s valuation allowance of $55.2 million and incremental release of the valuation allowance of $58.2 million for the periods ended September 30, 2023, and December 31, 2022, respectively. As a result of Evolent&#8217;s release of the valuation allowance, income tax expense was calculated as 26% of its loss in the December 31, 2022 period, excluding permanent items. Because the tax rates used for these pro forma financial statements are an estimate, the blended rate will likely vary from the actual effective rate in periods subsequent to completion of the acquisition.</font></div><div style="margin-bottom:8pt;padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;To record dividends and accretion on preferred stock of $2.7 million and $31.3 million for the periods ended September 30, 2023 and December 31, 2022, respectively. This adjustment reflects an estimated dividend on the Company's $175.0 million of Series A Preferred Stock sold to Ares Capital Corporation for the nine months ended September 30, 2023 and year ended December 31, 2022. The dividends on preferred stock were calculated to be 11.5% (Adjusted Term SOFR Rate of 5.3% on September 25, 2023 plus 6.2%) multiplied by the current liquidation preference of $175.0 million.</font></div><div style="margin-bottom:8pt;padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;The pro forma adjustments on Evolent common stock and basic and diluted earnings per share are summarized below&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:0.08pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.307%"><tr><td style="width:1.0%"></td><td style="width:55.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.254%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.255%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">For the Nine Months Ended September 30, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">For the Year Ended December 31, 2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Numerator</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Basic and diluted combined pro forma net loss attributable to Evolent common stockholders</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(94,851)</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(76,406)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Denominator</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Historical basic and diluted weighted average Evolent shares outstanding</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">110,464</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">93,699</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Shares of Evolent common stock to be issued</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">937</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">8,475</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pro forma basic and diluted weighted average Evolent shares outstanding</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">111,401</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">102,174</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pro forma basic and diluted loss per share attributable to common shareholders of Evolent Health, Inc.</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(0.85)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$                ($0.75)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>evh-20231102.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:90e52ce1-dec2-482d-8850-7e0869b345ac,g:fa62104d-c26f-4dc4-a3b6-8e40cb2ba55f-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:evh="http://www.evolenthealth.com/20231102" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.evolenthealth.com/20231102">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evh-20231102_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evh-20231102_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.evolenthealth.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>evh-20231102_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:90e52ce1-dec2-482d-8850-7e0869b345ac,g:fa62104d-c26f-4dc4-a3b6-8e40cb2ba55f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SecurityExchangeName_0a08423d-ab4a-41cb-b2ed-30b251d515b3_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_f1465eee-bb18-4996-914f-0687aa496752_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_9579e18a-12ad-457d-8866-8accba2f4ed2_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_29a35f51-b91b-4f75-90fc-c5734c9fabe0_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_b54f960b-a714-4b0c-b2e4-a30c58b7ea82_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_0e42073e-7c01-4b12-ae4b-8571a0def3a8_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_ca54180c-0264-4b52-9474-4085f9ca1125_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_dc72b1bd-71e7-4797-99a1-591a387d2a8d_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_18d00cb8-31e8-4712-bd86-d171e2f5a59c_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_a8d78bbf-636a-49b7-b1e9-e73a036d325b_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_c9aacb31-33a0-4bc2-9059-bcc88c6126cf_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_6ec350a5-1728-46bd-a663-3a422f67e39d_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_877d2560-507f-479a-8f44-8d0be9d9523a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_e0ee5abb-ed44-416b-b24e-9390e3eda2c1_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_dd0c0cfa-5ad1-4af1-8cdf-ecb5d31cd224_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_656bc31d-4e1f-490b-8e60-bc0a3a4f9ee1_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_2223ddf4-3bf2-4ead-867c-25d22e64e685_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_30bfd4c5-ed80-4825-9389-4415a7bc3ffa_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_91852dd2-8217-4476-a4bc-e19a55d46b27_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_79878694-80c6-412c-91c0-74f5ca6293cc_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_3dcb9784-2518-45e7-a3c2-cde53108ac5f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_b8608c84-14bf-4e28-9d6d-6cde1a4280d8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_65f99ab7-81fd-4a39-ba73-8a34b32eb0fc_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>evh-20231102_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:90e52ce1-dec2-482d-8850-7e0869b345ac,g:fa62104d-c26f-4dc4-a3b6-8e40cb2ba55f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.evolenthealth.com/role/Cover" xlink:type="simple" xlink:href="evh-20231102.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_434ae93c-925c-4d69-8d40-c21b240262e1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_4b5d594e-af2e-4209-8ccb-eb91de9681be" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_434ae93c-925c-4d69-8d40-c21b240262e1" xlink:to="loc_dei_DocumentType_4b5d594e-af2e-4209-8ccb-eb91de9681be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_f9b869fc-4dee-47aa-a5d8-070c5f975f8a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_434ae93c-925c-4d69-8d40-c21b240262e1" xlink:to="loc_dei_DocumentPeriodEndDate_f9b869fc-4dee-47aa-a5d8-070c5f975f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_b03acd77-75c1-4f6a-9ccd-175fdeb0deef" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_434ae93c-925c-4d69-8d40-c21b240262e1" xlink:to="loc_dei_EntityRegistrantName_b03acd77-75c1-4f6a-9ccd-175fdeb0deef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_8c5f8779-f2e4-4408-9f08-6dae307f181e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_434ae93c-925c-4d69-8d40-c21b240262e1" xlink:to="loc_dei_EntityIncorporationStateCountryCode_8c5f8779-f2e4-4408-9f08-6dae307f181e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_a73475aa-32c1-4953-8562-0a004c1b748d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_434ae93c-925c-4d69-8d40-c21b240262e1" xlink:to="loc_dei_EntityFileNumber_a73475aa-32c1-4953-8562-0a004c1b748d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_b30842f5-4db5-4121-baa1-ae927d3ba234" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_434ae93c-925c-4d69-8d40-c21b240262e1" xlink:to="loc_dei_EntityTaxIdentificationNumber_b30842f5-4db5-4121-baa1-ae927d3ba234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_12b83d63-e1ed-4cd1-9dc2-7674d2af9b97" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_434ae93c-925c-4d69-8d40-c21b240262e1" xlink:to="loc_dei_EntityAddressAddressLine1_12b83d63-e1ed-4cd1-9dc2-7674d2af9b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_81ba4180-c262-442a-a154-aa7845ad3c3c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_434ae93c-925c-4d69-8d40-c21b240262e1" xlink:to="loc_dei_EntityAddressAddressLine2_81ba4180-c262-442a-a154-aa7845ad3c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_a0b3b991-e2c1-402c-9057-01b7cd88948e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_434ae93c-925c-4d69-8d40-c21b240262e1" xlink:to="loc_dei_EntityAddressCityOrTown_a0b3b991-e2c1-402c-9057-01b7cd88948e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_38e939e6-3859-4687-9a46-8622c26716ef" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_434ae93c-925c-4d69-8d40-c21b240262e1" xlink:to="loc_dei_EntityAddressStateOrProvince_38e939e6-3859-4687-9a46-8622c26716ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_4249ad5e-b7ff-4a62-be7c-1fcc7d37f30f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_434ae93c-925c-4d69-8d40-c21b240262e1" xlink:to="loc_dei_CityAreaCode_4249ad5e-b7ff-4a62-be7c-1fcc7d37f30f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_6fdc358b-baf8-440e-8954-1c4a4d21c65d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_434ae93c-925c-4d69-8d40-c21b240262e1" xlink:to="loc_dei_LocalPhoneNumber_6fdc358b-baf8-440e-8954-1c4a4d21c65d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_9926a310-faf6-4014-8bbb-3421f9e9982d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_434ae93c-925c-4d69-8d40-c21b240262e1" xlink:to="loc_dei_EntityAddressPostalZipCode_9926a310-faf6-4014-8bbb-3421f9e9982d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_7ec22ae3-2925-4cdc-ba6a-1d10e5b66b77" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_434ae93c-925c-4d69-8d40-c21b240262e1" xlink:to="loc_dei_WrittenCommunications_7ec22ae3-2925-4cdc-ba6a-1d10e5b66b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_e6c2264a-bf41-4a65-acbd-bc15800e1be0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_434ae93c-925c-4d69-8d40-c21b240262e1" xlink:to="loc_dei_SolicitingMaterial_e6c2264a-bf41-4a65-acbd-bc15800e1be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_9891e177-e6fb-4fb0-ade4-3d1863e7585b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_434ae93c-925c-4d69-8d40-c21b240262e1" xlink:to="loc_dei_PreCommencementTenderOffer_9891e177-e6fb-4fb0-ade4-3d1863e7585b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_2b59d568-b5f7-4971-8419-52f538376e94" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_434ae93c-925c-4d69-8d40-c21b240262e1" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_2b59d568-b5f7-4971-8419-52f538376e94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_5dabaa1b-3d03-4071-be94-50b793ce496a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_434ae93c-925c-4d69-8d40-c21b240262e1" xlink:to="loc_dei_Security12bTitle_5dabaa1b-3d03-4071-be94-50b793ce496a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_f9069ebb-4162-43ed-aee0-e0392cc8adeb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_434ae93c-925c-4d69-8d40-c21b240262e1" xlink:to="loc_dei_TradingSymbol_f9069ebb-4162-43ed-aee0-e0392cc8adeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_80474f3b-411b-4b3b-8188-dc92496014bd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_434ae93c-925c-4d69-8d40-c21b240262e1" xlink:to="loc_dei_SecurityExchangeName_80474f3b-411b-4b3b-8188-dc92496014bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_16600854-2410-4ba4-99c8-151601a47aab" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_434ae93c-925c-4d69-8d40-c21b240262e1" xlink:to="loc_dei_EntityEmergingGrowthCompany_16600854-2410-4ba4-99c8-151601a47aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_3ad4181a-ce5c-4cfe-9e00-37591edefa22" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_434ae93c-925c-4d69-8d40-c21b240262e1" xlink:to="loc_dei_AmendmentFlag_3ad4181a-ce5c-4cfe-9e00-37591edefa22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_110b6fb0-30cf-4c4b-98b8-8845306587b8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_434ae93c-925c-4d69-8d40-c21b240262e1" xlink:to="loc_dei_EntityCentralIndexKey_110b6fb0-30cf-4c4b-98b8-8845306587b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_1a.jpg
<TEXT>
begin 644 image_1a.jpg
MB5!.1PT*&@H    -24A$4@   P8    *" 8    .[$DR    "7!(67,  $SE
M  !,Y0%USO"5    4$E$051XG.W.L0T ,!"$L-M_Z60,BC>2>[;M 0  Y^4#
M  ! +Q\   !Z^0   -#+!P  @%X^    ]/(!  "@EP\   "]?    *@]29(D
72>?[PB0H_'BRS/H     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>magellanlogoa.jpg
<TEXT>
begin 644 magellanlogoa.jpg
MB5!.1PT*&@H    -24A$4@  !6T   (_" 8    ,=OO!     7-21T( KLX<
MZ0    1G04U!  "QCPO\804    )<$A9<P  +B,  "XC 7BE/W8  +W1241!
M5'A>[)T'?%O5W8;-W@5*2\=75EA)"*-0H(5N*"W0 70P6Z"433>T0($L)R$)
MV7N'$+)WR(Y']O"2Y+WW'O+4EM[OG*MKL)UK^\J69$E^G^_W?&[LJWO//?=<
M(;TZ^I\H$$(((8000@@AA/01MP=8G]6(;\Y*0]2$9$1]F$(II;0OCD_&>1\9
M\6Y\N8>A+2&$$$(((8000OI$K<6),4>J\*5I)IRN%4!02BG5+T-;0@@AA!!"
M""&$]!6/,+W.BD<V%N L-6C0#" HI93JEZ$M(8000@@AA!!"^H+#[5'*(5RW
M( .GR7((#&PII=0_,K0EA!!"""&$$$*(K]2T.3'J<!4NG&+RAK43-$('2BFE
M?9.A+2&$$$(((8000O0BRR&DU5KQ&Y9#H)32P,G0EA!"""&$$$(((7JPNSQ8
MEVG&M?,S$,5R")12&C@9VA)"""&$$$(((:0WO.40*G$!RR%02FG@96A+""&$
M$$(((820[O!X@%260Z"4TN#*T)800@@AA!!"""%:R'((:S+,&,)R")12&EP9
MVA)"""&$$$(((:0KU6U.?'"P A=,,7K#6I9#H)32X,G0EA!"""&$$$(((>VX
M/!Z8:JSXU88"G"F#6LZNI932X,O0EA!"""&$$$(((9(VIQN+C?4LAT II0,M
M0UM"""&$$$(((824-#GPKY@RG,]R")12.O RM"6$$$(((8000@8OLAS"@9)6
M_&15+LY@.01**0T-&=H20@@AA!!"""&#DU:'&XN,=;AZ7KJW'()4*SR@E%(:
M7!G:$D(((8000@@A@P]9#N&?^\MP'LLA4$IIZ,G0EA!"""&$$$((&3RXW![$
MLQP"I92&M@QM"2&$$$(((820P4&+PX4%*76X:B[+(5!*:4C+T)800@@AA!!"
M"(E\BIL<^/N^,IP[F>40**4TY&5H2P@AA!!"""&$1"ZR'$)<20M^]&DN3A_O
M#0(T P)**:6A(T-;0@@AA!!"""$D,FEQN)5R"%>R' *EE(:7#&T)(8000@@A
MA)#(HZC1CK^Q' *EE(:G#&T)(8000@@AA)#(P>GV(+:X!3]D.01**0U?&=H2
M0@@AA!!"""&108O#A?DI=;B"Y1 HI32\96A+""&$$$(((82$/THYA+TLAT I
MI1$A0UM"""&$$$(((21\<;@]V%O8C!^N9#D$2BF-&!G:$D(((8000@@AX4FC
MS8WI"36X=)I)O,$7;_)9#H%22B-#AK:$$$(((8000DCXD5UOPS/;BW"FG%DK
M93D$2BF-'!G:$D(((8000@@AX8,LA[ SOPFW+\ORSJR5@:W6&WY**:7A*T-;
M0@@AA!!"""$D/#BU'$*7-_F44DHC0X:VA!!"""&$$$)(Z)/5M1R"UIM\2BFE
MD2%#6T(((8000@@A)'21Y1!VY#?AVTNSO&$M UM**8U\&=H20@@AA!!"""&A
M2:/-A6DG:W )RR%02NG@DJ$M(8000@@AA! 2>F36V?#TMB*<P=FUE%(Z^&1H
M2P@AA!!"""&$A YVEP?;<YMP*\LA4$KIX)6A+2&$$$(((800$AJ8K2Y,.5&-
MBZ>R' *EE YJ&=H20@@AA!!"""$#3T:M#4]N5<LA3.#L6DHI'=0RM"6$$$((
M(8000@8.60YA6VXCRR%02BG]0H:VA!!"""&$$$+(P,!R")122C5E:$L((800
M0@@AA 07CS"UQHHG6 Z!4DJIE@QM"2&$$$(((820X&%QNK$NTXQKYV=X2R$P
ML*644MI5AK:$$$(((8000DAPJ&QUXKT#%3ASDH'E$"BEE'8O0UM"""&$$$((
M(22PR'((295M^.7Z?)PV+MD[PU;K33JEE%(J96A+""&$$$(((80$CC:G&VLR
MS1@R+]T;UG)V+:64TMYD:$L((8000@@AA 0&60[AW?@*G#%1ED-@8$LII52G
M#&T)(8000@@AA!#_(LLA)%2VX:'V<@A<;(Q22JDO,K0EA!!"""&$$$+\1WLY
MA&M8#H%22FE?96A+""&$$$(((83XA\[E$,2;;@:VE%)*^R)#6T(((8000@@A
MI']X/,#)BC8\M([E$"BEE/I!AK:$$$(((8000DC?:7.XL2K=C*OGLAP"I912
M/\G0EA!"""&$$$((Z1OE+4[\-ZX<IT^4;["%#&PII93Z0X:VA!!"""&$$$*(
M;[270_C%VCQ$C4MB.01**:7^E:$M(8000@@AA!"BGU:'&Y^F-^ JED.@E%(:
M*!G:$D(((8000@@A^BAI<N _<>4XC>40**64!E*&MH000@@AA!!"2,\XW!X<
M+&G!#U;F(&J<G%W+<@B44DH#*$-;0@@AA!!"""&D>YKM;LQ.KL579Z2J@:W&
MFVM**:74GS*T)8000@@AA!!"M,EOM.'UO:4X37T#S<"64DII4&1H2P@AA!!"
M""&$=$:60X@O:<'W/R^'H/&&FE)**0V4#&T)(8000@@AA) O:+*[,#.Q%I>Q
M' *EE-*!DJ$M(8000@@AA!#B)==LPZM[2M4WS$(&MI122@="AK:$$$(((800
M0@8[[>40[F4Y!$HII:$@0UM"""&$$$(((8.91IL+,Q)K6 Z!4DIIZ,C0EA!"
M""&$$$+(8"7';,,KN]O+(3"PI912&B(RM"6$$$(((800,MBPNSR(+6[!/9^P
M' *EE-(0E*$M(8000@@AA)#!1'LYA"^S' *EE-)0E:$M(8000@@AA)#!0DY#
MQW((7=X@4THII:$B0UM"""&$$$(((9&.+(>POZ@%WUO!<@B44DK#0(:VA!!"
M""&$$$(BF7JK"]-.UN#+TTT,;"FEE(:'#&T)(8000@@AA$0B'J&QVH)GMA6I
M;X"[O"&FE%)*0U6&MH000@@AA!!"(@VKTXV-V6;<NB23LVLII92&GPQM"2&$
M$$(((81$$M5M3D0?K60Y!$HII>$K0UM"""&$$$(((9& +(=@J+;@Z:U%WJ"6
MY1 HI92&JPQM"2&$$$(((82$.Q:G&QNRS+AE,<LA4$HIC0 9VA)"""&$$$((
M"6=D.82Q1RIQ*<LA4$HIC109VA)"""&$$$(("4<\'F\YA*=8#H%22FFDR="6
M$$(((8000DBX(<LAK,LT8P3+(5!**8U$&=H20@@AA!!"" DGJEJ=&'VD$I=,
M8SD$2BFE$2I#6T(((8000@@AX8 LAY!29<&36PM9#H%22FEDR]"6$$(((800
M0DBHTZD<0C1GUU)**8UP&=H20@@AA!!"" EE*EL=&'68Y1 HI90.(AG:$D((
M(8000@@)160YA.0J"Q[?PG((E%)*!YD,;0DAA!!"""&$A!HM#C=6I3?@)I9#
MH)12.AAE:$L((80,'CP>E_S_WG\00@@A(4I9BP/OQ%?@K$D&[^Q:!K:44DH'
MFPQM"2&$D,C&Z6J&Q5: NJ88E->O0[5Y&YK:#+#:R\3?FM0@EQ!""!EX7![@
M:%DK?KXV'U%CDQC64DHI';PRM"6$$$(B$X_'@6:+"3EEHW D_2[$FZY'?.HP
MX5 <2!V!A)Q?(;OL/534KQ';&6&UE\+I:F2(2P@A9$"0Y1"6FNIQS;QTED.@
ME%)*&=H20@@AD8?'XT25>0N.9?X8<<8A:E@[# ?4GY]KDLH0]R8DY/P2667_
M8XA+""$DZ)0V._!V7#G.;"^'H/7FE5)**1U,,K0EA!!"(H_:YOTXD7T_8HW7
MX$#J<"64U5;^C2$N(820@<'E\>!(62L>6).'J#$LAT II91^+D-;0@@A)+*P
M.:IA*'@.,88K.H2S>F6(2P@A)#BTET.XFN40**64TE-E:$L((81$%N5UG^)P
M^EV(,]W0(8SMJ]V'N"=S'D96V;NHJ%^-)HL!%GL)'"XS0UQ"""&]4M)LQW]9
M#H%22BGM7H:VA!!"2.3@@1L9)?_"?L/_=0A>_6F'$%<-<.---RJ_;P]QRQGB
M$D((Z099#N%P:2ON9SD$2BFEM&<9VA)"""&1@\-IAK'P!<08KNP0M 92&>(.
M[S 3ER$N(800;9KM;BPRUN,JED.@E%)*>Y>A+2&$$!(YV)VU,!0\CUCC51V"
MU6#*$)<00LBI%#?;\9_8<IPQD>40**644ETRM"6$$$(B!QF IA6]@1C#MSH$
MJ0.IWA W!19[$>S..K@]-O5L""&$A#NR',(A60YA=2[+(5!**:6^R-"6$$((
MB2SR*L8CSG0=9.U9[2!U(-4.<0^*OQW/N@]I17]%<<U"F%N/H\V6K\P<9HA+
M""'AB2R'L-!0AROGLAP"I912ZK,,;0DAA)#(HK9Q%XYE_50-;KN&IJ&F5H@[
M%''&ZW T\P=(+Y8A[@*&N(1$(,U.#^H<7LU"\4\2010UV?%F3#E.9SD$2BFE
MM&\RM"6$$$(B"YNC D:EKFVP%B/SISI#W!:&N(2$*Y4V#W96._&?3 N>-UGP
M9^'KZ1;,*;8CJ<D%FUO=D(0E#K<'L<4MN&\5RR%02BFE_9*A+2&$$!)YY%5,
M#.$2";[($)>02,'E 8Z977@DL0U1GS4B:D<7MYGQS=@F?%1@0[V#TV[#D7JK
M"S,3:W#9]%1$C6,Y!$HII;1?,K0EA!!"(H_:QCTXEG5?F)1(\,6>0]RTXC?4
M$/<8VFQYL#MKX'9;U5XAA P4;2X//BYSX,K89D1M5T/:G1JJ8>ZK:58T,+@-
M*[+JK?C+CF)O6,MR")122FG_96A+""&$1!XV1R4,!<\BQG!%E] STM1>V"S.
M>*T2XJ86O8'BZOEH:#G*$)>0 4+6JYV09\-%>YJ\H:Q66-O1'8TX2_P<+Q[#
MV#;TD>40=N4WX;LKLA$UEN40**644K_)T)800@B)3'+*1R'&>)4:;'8-.R-5
M;X@KRT*<&N)^GR$N(4&FQ.K&&VD6G+.[J?O9M5IN,^.')UJ0U\8"MZ%,G<6%
MZ0DU^/)TDW>&K=8;3DHII93V38:VA!!"2&12:=ZLS#:--UW?(=0<;#+$)62@
MR&QQX0_)K=YR"%K!;$]^UHB+]C8JBY.1T$260_@SRR%02BFE@9.A+2&$$!*9
M6&R%2,Y_$C&&*SN$F(/=[D/<(TJ(^SI#7$+ZB5QP+*[>B1\>;U5FS&J&LGK<
M:L8_,WC_A1J?ET/XF.40**64TH#*T)800@B)7+++WD.L\6HUJ.P:8-+>0]S7
M4%0]#PTMA]%JRX7=4<T0EY >D N.+2UUX%OM"XYIA;%ZW6+&:^D6=<\D%*BU
M.#&-Y1 HI932X,C0EA!""(E<JLQ;6"+!)WL*<>]50]RYJ)<AKC6'(2XA'9 +
MCLG%PR[<TZAOP;'>W&+&&PQM0X;,.BN>9SD$2BFE-'@RM"6$$$(B%XNM""GY
M3R%669"L:T!)>[<]Q!U^:HB;<0]#7$)4BJUNO-Z7!<=Z<HL9KXI]DH'%[O9@
M9UX3[F8Y!$HII32X,K0EA!!"(IO,TK<18[BB0Q!)^ZXO(:ZWG(*+(2Z)<#):
M7/A]7Q<<Z\FM9CR>T@:'1ST0"3IU%I=2#N%2ED.@E%)*@R]#6T(((22R*:E=
MAD-IMROAHG802?MN;R'NJRBLGH/ZYH-HM6;#YJB"R\V9@R0R<'J F#HG?G"L
MGPN.=:?8YT.)K:BR,[4="-)JK7CN,Y9#H)122@=,AK:$$$)(9--BS4)2WN_4
M!<FZAH[4OW87X@[I$.+.9HA+PIY6EP>+2QWX/W\L.-:=V\QX.+$5U0QM@XI=
M7-O/\IKPG>6R'$(BRR%02BFE R5#6T(((232\2"C^%^(,5S9(5RDP9$A+HD\
MZAT>C,VSX0)_+3C6G0QM@TZ-Q8F/3M3@DFDLAT II90.N QM"2&$D,B')1)"
MQ=Y"W%<8XI*0ILCBQBNI%IRUN]%_"XYUYS8S?IG8BAJ&MD'!5&/%L]M9#H%2
M2BD-&1G:$D(((9%/BS4#27F_1:SQF@X!(AUX^Q+B<F$S,C"DM;CP6&( %ASK
MSFUF/)C0B@H;0]M TNIP8WV6&3<MSD34V"260Z"44DI#18:VA!!"2.3C\EB0
M5OQ7ED@(>7L*<;_7(<0]@%9K%FR.2L[$)0%'+CBVK\Z)>X\&:,&Q[A3'NOMH
M"U*:7&I+B+^I;'7@O0,5.'>R@>40**64TE"3H2TAA! R."BJGJ4$@_&I0]6
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M[6;<=+ 9L75.M1<B UD.82_+(5!**:6T)QG:$D(((4127#T7!U)'(#YU:)<
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MK?U1ZJN^C$$]XT[OO1H.]R>E-#@RM"7$O\QY>Y=25_;IFX,[V_8I<;R7OK\
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MMJM[Z9W$*@N^.CMMX(.S4 QMQ7[/$/Y6Y\Q728'H>WGOZAY;'97G(61H2^D
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MGN3NK21)"S^C+0  P/RVL74X+M_8$9^XNR:6+"^\D4M^<)G3"9(D+=R,M@
M *6AMG<T;J_JB:^L:HBW7+BE^.3M4N.M)$D++J,M  ! :>D9R<:JZOXX[=F6
M>/]UVXHW;Y.<3I D:6%DM 4  "A-^4+KFH?B^^O:X_=NW1G'G%,6J=.=3I D
MJ>0SV@(  )2^RHYTW%;9'5]XJ#[>]/W-D3IM7:3.,MY*DE22&6T!   6CL[A
M3#Q<W1???JHY?O[*RN*3MTXG2))46AEM 0  %IYL/F+M[L$X[^6V^.V;=D9J
MV4:G$R1)*I6,M@    M;14<ZKM_<%7]U?UV\^<(MD3IMO=,)DB3-YXRV
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MI):Z>RM)FN.,M@   "QVF7P^-K4-Q_6;N^(/;MM5?.HV&7"=3I DS45&6P
M -AK1_=(W%[5$U]\N"'>?.$6=V\E2;.?T18    .UC&4B2?K!^*T9YKC%ZZN
MC-293B=(DF8IHRT   "\NM%L/M:U#,5EFSKCY!].G$Y(!MQEGKZ5),U01EL
M  "8FET](_'#RI[XS/VU<>+YY4XG2))F)J,M    ')JF@;%XO&X@_NWIYOC9
MR[8ZG2!)FMZ,M@   '!XTIE<O-@T%!>L:X\/W+"]^-2MTPF2I"/-: L   !'
M;DM[.F[9VAU_>G=-_/@*IQ,D24>0T18   "F3WW?:#Q2TQ__]$1C_*?+*B+U
MW?7%'UXVV9MR29(FRV@+    TV]@+!?/-0[&LN=;X]>2TPGNWDJ2IIK1%@
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MXM/WUL51RS<YG2!I\66T!0   .:CIH&Q6%/7']]ZLBE^]O*M3B=(6CP9;0$
M (#Y;& T%V5MPW')^H[XC1_L* ZWR?D$XZVDA9K1%@   "@%N7S$]JZ1N*VR
M)SYQ=TT<L[QLXNZMTPF2%EA&6P   *#4[.X?B\=J!^*KJW?'6R_>XNZMI(65
MT18    H55WI;&QH'8X+U[7'+UY3Y>ZMI(61T18    H==E\Q-;.=-Q<T14G
MW[XKCCW7Z01))9S1%@   %A(ZGI'8W5-?WS^H8;XC\GIA*5.)T@JL8RV
MP$+4/I2)YYL&XSO/-,=_O38YG3 QWCJ=(&F^9[0%    %K*AL5Q4=*3CJDV=
M\;';=A:'V_'3"9,,)9(T'S+: @   (M%;>]HK*KIB\_=7Q?'GC-Q]S89<2<;
M321IKC+: @   (M-VV FUC8,Q+^O;8EW75$9J3.=3I TCS+: @   (O5X%@N
MMG2DXXJ-'?&;-^V(U/<V1>HLXZVD.<YH"P   "QV^4*[>D;BSFT]\<F5M7'<
MN1.G$Y89<"7-049;    @+V:!L;BR8:!^/O'&N.G+ZF(U%*G$R3-<D9;
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MSOC(+3N+0XS3"9*FDM$6    8&;5]H[& [OZXO,/-8P/,<7QUH KZ54RV@(
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MOOC< _5QXOE.)T@ED]$6    8&%K'\K$\XV#\7>/-<8[]YQ.,-Y*\S>C+0
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M'V\-N%K(&6T!    F,^&,[FH[1V-.ZIZXG=NV5D<;_>]?3O9Z"65<D9;
M $I%X\!8/%K;'Y][H"[>_,KIA(DF&[^D4LQH"P   $"IZ1K.1GG[</S+4TWQ
MWE=.)^S39$.85"H9;0$    H58-CN=C9/1*7;NB(W[UUS^F$0DXGJ)0SV@(
M  !0ZC*Y?#0-C,5].WKC?]Y?%R><5V:\5>EFM 4   !@(>D<SL:FMN'XQR>:
MXBT7[KE[.S'>&G!5"AEM 0   %B(^D=S4=F9CDO6=\0'?K!][VCKZ5O-]XRV
M     "QDR>F$QOZQN'=';_S)RIHXX;QRIQ,TOS/: @   +!8M ]EXIG=@_'5
MU;OW.9TPT63CF307&6T!    6&QZ1[*QM6,DEKW0&N^[IFKO<.OI6\V'C+8
M    +%;I3"[J^T;CGNV]\;';=A4'6Z<3--<9;0$    @HG4P$T\U#,2I#S7$
M3R:G$UYY^G:?,4V:C8RV     +!7=SH;%1WI^/>U+?&^:[;M,]YZ^E:SE-$6
M      XV-):+NKZQN&5K=_%TPOB85LAXJYG.: L     KRY?J&4P$P]5]\7_
M>K ^7G=^N2=O-;,9;0$   !@:I+3"5LZAN/;:YOCG5=43HRW209<36-&6P
M   X-,GIA.J>T;AB4V=\^*8=Q<'6Z01-5T9;     #@\F5P^F@?&XL%=??&I
M>VKC]4XG:#HRV@(   # D>L<SL9+S4/QKT\UQ]LNWC(QWB89<'6(&6T!
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M,X[:<SK!W=O%D]$6     .:?;#X_?CKAD9K^^,Q]=?N<3DC&6Z<3%G1&6P
M  "8W[K3V5C?.ARG/=,2/W-I11R5#'M.)RS<C+8     4!K2R>F$WM&XIKPK
M?NV&[7'T\C+C[4+,: L     I24YG= Z6#R=\(F[JN,-%Y07QSYW;Q=&1EL
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MC&/.661/WQIM 0   (#Y:#B3B\;^L5CQ<GO\\O7;BZ<3)D;-!3W>&FT!
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MN:HJCCMW'IY.,-H"     (O-R,3IA$LW=,1';]E9/)TP,9C.^>D$HRT
ML%AE<OGH3F?BWAU]XZ<3?GS%YCAZ^3ZG$R8;56<ZHRT     0,3@6"[6-0_%
M/S_9%"==6A''G3-'=V^-M@      >Z4SR>F$L;AH?7N\]^JJ."&Y>SLQIL[*
M>&NT!0     X6'(ZH6,X&_=L[XT_65D;)ZXHCZ,G1M7Q#AQ;IRNC+0    #
M:QL8S<6ZEJ'XV\=VS_SI!*,M     ,#4#&=R4=TS&A=OZ(C_<LVVXNF$9+2=
MSO'6: L     <&B2TPF=PYFX:6M7?.R'N^+$\\MCR<3@FEIVA*<3C+8
M (<GEX_H&\W&R\U#<>I#]7'2)15QS)&>3C#: @     <N>1TPL[ND?BWM2WQ
MBU=7Q?&'>SK!: L     ,'U&L_GH&,[$%9LZXP]NVQ4GKBB/HR;&V/$.'&D/
MS&@+     ##]LOE\](WFXJF&@?@_#];'&R_8',<LG\+I!*,M     ,#,&LKD
M8E/K<'S[Z>9XQ^5;X_CD[NVKG4XPV@(     S([D=$+[4":NV-@9'[YI1[S^
M_/)8DHRV9R7C[<3I!*,M     ,#LRN4C>D=R\>"NOOC4O;7QQ@O*]YY.6+HA
M3C#: @    #,C:&Q7&QL'8ZO/]X8;[^L(HX_9U,<=VY9?/-)HRT     P)P9
MR>:CKF\T+MG0$1^\<7N<MK;9: L     ,!\D3]_NZ$[G_S^R+%=+X!:N;
*  !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140470857393888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 02, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  02,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Evolent Health, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">32-0454912<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">800 N. Glebe Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Arlington<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">VA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">389-6000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">22203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class A Common Stock of Evolent Health, Inc., par value $0.01 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EVH<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001628908<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>evh-20231102_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="evh-20231102.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2023-11-02</startDate>
            <endDate>2023-11-02</endDate>
        </period>
    </context>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-22">2023-11-02</dei:DocumentPeriodEndDate>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-23">0001628908</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-24">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2023-11-02</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Evolent Health, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-37415</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">32-0454912</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">800 N. Glebe Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-8">Suite 500</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-9">Arlington</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-10">VA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">22203</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-12">571</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-13">389-6000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-18">Class A Common Stock of Evolent Health, Inc., par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-19">EVH</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-20">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-21">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( "NA8E<'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  KH6)7_G4.N.T    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M2L0P$(=?17)O)VE!,'1[6?&D(+B@> O)[&ZP^4,RTN[;V\;=+J(/X#$SOWSS
M#4RGH]0AX7,*$1-9S#>3&WR6.F[8D2A*@*R/Z%2NYX2?F_N0G*+YF0X0E?Y0
M!X2&\UMP2,HH4K  J[@26=\9+75"12&=\4:O^/B9A@(S&G! AYXRB%H ZY>)
M\30-'5P!"XPPN?Q=0+,22_5/;.D .R>G;-?4.([UV);<O(. MZ?'E[)N97TF
MY37.O[*5=(JX89?)K^WV?O? ^H8W;25$Q=L=YY+?R4:\+ZX__*["+AB[M__8
M^"+8=_#K+OHO4$L#!!0    ( "NA8E>97)PC$ 8  )PG   3    >&PO=&AE
M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?
MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@
MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?<D3$L/<@HL(2W@4R]9<
MX%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A T%116F]?(+3E'S/X%<M4C66C 1-7
M02:YB+3R^6S%_-K>/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1
MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP
M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?=
MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP
M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%,
M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I
MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88<G;CL3<CH<9T)\S_;VD:4E
M,L_O^0KK3CQG'U:6L%W/S^2>C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ
MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A
M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;S<HY=8%0&7&-\TJC4LQ=9XE<#QK9P\
M'1,2S90+!D&&ER0F$JDY?DU($_XKI=K^G-- \)0O)/I*D8]ILR.G=";-Z#,:
MP4:O&W6':-(\>OX%^9PU"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:
M<K46@;9QJ81@6A+&T7A.TK01_%FL-9,^8,CLS9%USM:1#A&27C="/F+.BY 1
MOQZ&.$J:[:)Q6 3]GE[#2<'H@LMF_;A^AM4S;"R.]T?4%TKD#R:G/^DR- >C
MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_
M+GW/I>^Y]#VATK<W(WUGP=.+6]Y&;EO$^ZXQVM<T+BAC5W+-R,=4KY,IV#F?
MP.S]:#Z>\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"<M4TV4WBA*>
M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT
ML<QP3A[+##MG/)(=MG>@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3
M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'
M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\
M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^
M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON<K2<15.+]%,[82EQB\X^;'
M<4Y3N!)VM@\",KF[.:EZ93%GIO+?+0P)+%N(61+B35WMU>>;G*YZ(G;ZEW?!
M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4<!A87,N10[I*0
M!A,!S93)1/ "@F2F'("8^@N]\@RY*17.K3XY?T4L@X9.7M(E$A2*L P%(1=R
MX^_ODVIWC-?Z+(%MA%0R9-47RD.)P3TS<D/85"7SKMHF"X7;XE3-NQJ^)F!+
MPWING2TG_]M>U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83
M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'
M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MCMQC)8QQ8K3^-8+)#^Q^ %!+ P04    "  KH6)7JL0B%C,!   B @  #P
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M2P$"% ,4    "  KH6)7_G4.N.T    K @  $0              @ &O
M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    "  KH6)7F5R<(Q &  "<)P
M$P              @ '+ 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0
M   ( "NA8E>.PB3X8@0  #D1   8              " @0P(  !X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"% ,4    "  KH6)7GZ ;\+$"  #B#
M#0              @ &D#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( "NA
M8E>7BKL<P    !,"   +              "  8 /  !?<F5L<R\N<F5L<U!+
M 0(4 Q0    ( "NA8E>JQ"(6,P$  "("   /              "  6D0  !X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  KH6)7)!Z;HJT   #X 0  &@
M            @ ')$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4    "  KH6)799!YDAD!  #/ P  $P              @ &N$@  6T-O
F;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  #X$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="evh-20231102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="evh-20231102.htm">evh-20231102.htm</File>
    <File>evh-20231102.xsd</File>
    <File>evh-20231102_lab.xml</File>
    <File>evh-20231102_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "evh-20231102.htm": {
   "nsprefix": "evh",
   "nsuri": "http://www.evolenthealth.com/20231102",
   "dts": {
    "inline": {
     "local": [
      "evh-20231102.htm"
     ]
    },
    "schema": {
     "local": [
      "evh-20231102.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "evh-20231102_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "evh-20231102_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 24
   },
   "report": {
    "R1": {
     "role": "http://www.evolenthealth.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "evh-20231102.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "evh-20231102.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.evolenthealth.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001628908-23-000169-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628908-23-000169-xbrl.zip
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M./=]]$TWXWAE#<<!NN[.@+]7QZV2I]L'SN%F_$_[KI* G=HF'\R13I*,F'@
M7ZI/RI<BTTL'[F9\R?JN=KQF;[O%4<*5SRI80#&&7KC_-LTAJ&R/.1U"G20*
M1G)QR'U7YM)_!V(:@?>9[D!4\EVG/EBF!@UNZ#C1"D]]46\')7-F(TT]*B;
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M6"V8L!)J5\A.&MUP-IH\N\)85V:GC;TH+PM>[>1>/,Q$GDX%P3$+?0%X!#'
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M='OH [3\S.'(,FX/9U/!'79=XEUGW,C]V]L7JW>2Q7?HOWWQ?U!+ P04
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M)@?K5 8F$X)HSWFVDX+U>>O#^ECL&Z%CC+2OC$@']E&#KB^AE%#618W@\Y1
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M[K6C,.U.87 ^GE+$[>I]4[_(=/\.]A5/WB^-%;/U7S&ET;]"R)4T;GM8!;9
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MX^TA^A!1K84(?(#P #@3!R -K ,.SHO?+BZN7S:<+S 58A1 :M@/(Q@9WBL
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M.KGW8_OTZ)F 5+M]=G!DJFK6?RB7.U2+6^>L=7"TB%G<0UG;D0[-L+:>VSU
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MFXG-//#AMW';^WI6Q^%W=?B#"[#O+L\A#R' ?M>'?U94]I@T\*1) XI*<=Z
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MJJ_.GP!4Z[7)]EQM\KH8CUG6=ZYAX>$ K@;6)[,H$9R^)D"F[/BR^\JVKGO
M3ZE[KTB"WQ(8PAE]30$9XKQ<:^CI#F272%])Z5[H.F-AOR\$DCL!JB\S6QP@
M#:@1( F[GH$Y$#M@$)##,F<(\F_J1417?#')C?3_!_!"^(OFR:1F_$?C&A2/
MBXNOK )S,"Z^#!( ^6P]_*36'B#SA-42L I8&I3- *B@#*L& X"((F)[0:+M
M+S2:]9*/HF5?01&.4)]+6II.R9!P&D"!J_I;69(; 6LP\T4J:Q!ESDQ;&_3(
M.&N<Y/C,PS.( X"S)!:.O%)>OH?*%)![^!Q&DLH8GEA!DIWX ?.AB-J 5<29
M^*N <XRF;FG VJ,F>,#Y2RLN TA_.F?'#X,[ H@9W;AT4VL""OV,7(U)!&LE
MY=-E (!C#0>U8JH%/R,OX)7#>H+"9[ /!&9-T2F7-P)B<83R,.@'^@:5'0MQ
M*ZPQ89G# <T)Q'/:L'PY)YZ?+=%X[C#$/.MB)#[BS<\<*<MASBUH3 G@2-EZ
MX4H#&QKP$;H1 -A<Y^)'=Z/0']7=$B%A$ *8Y31"2K8$V[#0 -5@(%)$Q<S1
MM[<8-=!,9)E&%EL[R=A)WU0,,D2A&.B5GBCB(8Q#1+HN<=E\$I 8F+,)%0_#
M=F@L)'8:7_07H:VIX@VQ=6?@ &%1!-<>_K,G5<@K%I"=BRQ+?%G"I&3[DL89
MMMK"7=RA;<W+:$0CAZ,N;":X2T/0U&.\9'VF7UG.3VGZ&_'#JT[TZ>N-UGY+
M%L"/X4# JUF1$JM4!%]_]_'JG;&Y76H3K+)KM92Q$5<\?YVVE0Y(#D8K\<V@
M.8T^TZ:IA@.7$6;FB7T-UIADZ2H9@N5:^#+G<P8B2G!6X6V58/\MJS'5+T&$
MC7)%)'B!RG!PSO;3_76V/V.&HXFW)MF(1U=<ZT^9%E(V##'4HX2923Z!PG*>
MIV&_X&+[@,:SO,K0,A0(HRCQV9*&!=VXO*4T7S,=&!2Q;T1;RT!H%:H %9TY
MFI34S*!CD8^2  V=R -L+,]\6&=)\C !>?GH/C9V-P*^AQ:(- $& #\K>X6<
M6ZB#*3,I:U^^=&R)JI%2'0([RQ(J &->SHH)_,L80X HVGLNS1N@:X8FZZ/M
M,\^C>OE6;9G/4*DY'.AL1 3\3:Z-_'I,^HQ:M AT-!NM>8/BJS]0MJFDGE*0
M,%N2"U.@(/4:DFC])4J^-YSWA5";#&.\.A@-A<]<@YZ!&?8#P?%),U.,CE;%
M!5F*J)QU*M3"O72LA80()!(\6\S2]!B$#UF<?5>DJ?)A!<J);8J(2FJB$<3[
MH8'-QEJ@\V,"(78 ) QZMJYCJ<66JH-@C_9"4MXL(],U?NDA!W^7!&2$(H#X
MG#2<TV[395N5)'\WN$K^Q;@.WN%[1E*KH7AU6A:K8F'.#G*CZL*V)]Y4H/>B
M 4@S2 #2[I3N?ZW>^B;R(HV=3YJV35\>,F252,M;+R)$O1X)805;>,1Q:BT?
M6C&HLBXZ\WG.ZP:*[G7# 37,1J3R:VWE3F@[N2&7]QHKY K(7YL;TTU9YR O
M9*W)XFI6F7%(>.:Q> @:("V9AEP%EN*'7##N(Q5*];^7-\+)H'N] )81PD^9
M9!]DM2'MC#B:T4Z!E=(O\M30Y(Y_WX69<.E>0'P&?5&H59(^D$1UVIHT'VG[
M@MK!L@O_H@4)C;0@'*3!*S1DH>>US_2+5!I)J<CX@>Y<;5RBN0V/@'LLI",E
MGJI-,'/-+'T!HV+@,BQAQJB;2<JNXJHX@8,:T8 +>!4I*J%&(\$5S97.+ K9
ML,,/W!+M#$*VV@U!F?)@L1R[1*<1PPK"K/3VGTE(AB(6UVZE$151!.;$%?/N
M0*7"$8Z$BT^MR(& _$=DEB!FG'L"-6!\'*#<ZU-58S[?:48H1H" UV_[UX"3
M )Y$+L*$/_(R<L@1^T5A$\$ ;KI!W) \V&A"Q4%<#=L5L"__7 9\!GH)7@SU
ML^0GOA<)V3-?)GT6*3%3D4&(S#Y 1R)CS-'0C(>+=:++\D FT<26RC# X0['
MM*%8H;D4/1&34C' Z".C,^#P6F;&"CYC2WRNCPWL2_:4$7NJX%S]>%JZK(4-
M?0MR6BV5XV"2X\VCE)61_6)<L+U!-B#12RA9#9TZHZX*%"+"0'X13=E<9GT9
MC@LKL68QLKJ\I(,/,3*"@!UCHD4'5$M"#,"9$CV.!9("I5D2<$H.*:'-#*?L
M0VZ]VP@0WU1=KP=#TO6-LE4'4Q($!P7'!6/(@4<KFCIW21'9K!G=#"7QG,B'
M%H3+OAS"<:!#1:I$X1GVN1+D;.F"E^QQ>383\%_KU#^SDX]VR%/-U'VQH_K!
M^]UG'%]L6%K.DQ<'I3#R.CRW- FX%:EHWX_$[-'+K)",>N\>\4>;B:[D[JOC
MD?<I%55'HV*EIN$ KTK6WS9LW4C4]+S6>X;>5W238.2N-)0IEA:72FV!F"%-
MC8^?ZK SR/W9<(0KS1$.)]5C!F) =Q%_%<B3DHI(6S$_6!)6C5YGN90J E=8
M$D99:@]M;1'T<XHTJ>75G)X!8T2A*"AP#SM)C9(HH,A<N?0AA<FOY?A5ZU,.
M9VWIL)S4&-EK!(Q%!N!Y8C33-\M.;IMH=5,\@YK&7(Y6>8$ZBGDXAQB45 8D
M,26:9B3^E:3]>FBP**%%;6@/1,(FN:9?3+91J=/JO#%G+C:A*[7?+!WNLZYL
MV^*5SQE^/M$[./_EV=[[+RL'5]_X&/;^5&36WL1N\+T_,E)9+^&XQJC4'@[+
MNR$3,6MCTD,V)YD1B1FJJLA2-A!.F0K*%BQEA8#,-?:^@QZH[H&I7)85XXF5
M]>)1#(JT@J"35%"/3I54.<?\K[A $&:8G"4S6M'(##L@-C'GNUP;.Q1QGANU
M-V]);)_B+ M+N^57Z0!)SVV40J3-*51<7.BOE%S3Q5FP?ANQ0Q3,A\ S;[VH
MT-<)LC1H_"%UJJ$=5IX/DR2X"]%\6-.'TCI[EWQU^KQ\=:8<L66=V (#LQ=E
M?,69M;LPUC('=\?E<TI--HH#M JV5^/.*WOS3IHGCNVQ@[]UR!,[)V0R7>01
M\T,32T+^\]P+HV-^SCKY.7 KE/6DS$T^&8#@4D :4_X8$&S,?6_"$?#46]X]
MCK4 )IX_T[HP09?5B$T3LD1X;87XF2!"=/NGP, NQ@*5,ADM:%SP;%4 /N$-
MAYCVE[.S3A$FE=XY%1ZZ-]%>^Q[D>DJ][L@(1+2DC[T_X4T9O^/@+H 83B?2
M.,[)1<PUT%Q"-3CK:-\+8I^@?<&KV<M2.?:=E>HL49E=D%H-H")WF-[M33+Q
M6OWC#1PV$.7IZS"F@>FC-S+-1>H.:#NLU+@C<.3'4F ^/V^<=6DULB:EG%B*
MTPUZ5*G+Q\_.NHW33F?NXV:C-??9HF%;G4;SY'2I89<LI;E$'?T%53=9E5JE
M=F*[TQJT'[-^*N)+J63B$Y7@S9/)EG;\B2C#M:0,'Y$L/:3NKETZLM$K%8]L
M'D"+A&\Z3WR)+@#[74EUCRJB=GINK]O;R:9]P9Z5Z[ZX_C*7/-Q34KNZU9TK
MJ3VGEW+KW#V]IYORLE=[Z&6M;Y)<^AVD=/F@LOK[33^?1:WI=J_GML_/MM\C
MH>(2D&[[378UK!;)WEA;P]UE ?42XXW4&]])O7%=<3&8UZ9ALP3O*43K>N3X
M+8&EQ"6W]5$8W/H6EBF/?Y0&EVQLE,2OAG.A_+D+ALOPOJ-@>!0,CX+AG@B&
MJXDI*XZQ85%R-[%[CL2HG0J+7$4K=C4Z!/YZ(T/),&@+@PV<">8Y41 #3/,0
MGK/G)'*I+>XVA5RJ3=-1?%@93U <K46/&G'TF4J=1_5EPU+G/3S]D/OI/>K1
M[#\J/NKY/&X'/M4$I7&F8'.O\AY7#&+Z"ESC$P?.T#_A@Y$.X/OZZ>LG';TG
M95B3_??$L#>3QOW(A<U=67BH%#R)L9@8V8313RGFBQ5]3!G+.1\L50&='%F:
M33#W@&(RISIDB:J$8F]36CT%.Z7"R\LK#ZF@ J6)<C4#9Q#^P.(\<"&.[TU4
M,1V9O^#J(NP7UU]6VI ^0STU98![F4R25X77;T-QYSK] M%59+*N*)Z%,RBB
MZ+Z]XK]G=^G.;C.N%F@:"$JDHU<SKHN%YTU?RR(6F7>+(;<'G\]< ](RB9\N
MF=H)4.RVRO:12 Y/!V'.I]E0@:5_4+2OIT?B<'/[53,J7N3 W'>>**CBWZA@
M9L:AJHX/]-G#N\14J %6%(^PQ4)6CE'&6&BU/)I,+4M/(B^=E\4)]2J:+U=9
MRQAGY0T)MG,$+Y,UK795[@/BZM69\U-G939;W9\F#:9GP:#@IA_VJ6# H3P)
MKP^RNBDN:9T"K.>MJK5$; @G2P8#W !68^(<@.HBRV=G)2.I_%&3M4E"GZI
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MJ40*"%Z2NI0Z[&!_/)8WL8Y@&G+!^'^-L,Y(]7>9EY+I0F&9**<XS0/C>]9
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MIRM[[6H3@OWCA6NU8$4WXAQ\#TT[/LN%0NQ\Q+U88.V@94K#",D6-ATH"?E
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MQ*,D55YU&3\Q4OU=LR(E/LPMPTCBJ7'3)ND0'O[',P3#>BCC6A:AP+-JH$B
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M=?@"S=.\(3Q9MQ(]2S=BW62EW>?#[LI:WOHW)0?8SD7IPZVY)_SQUY^[IV^
M[MYSH5=Z(LJUM'JLAY7>[A]T@O.UU=XUS].P7^2B9,K2?JK0'MV";65'HER?
M5YC^/:=];,VY<9D:(!FQ@AZ0B+-I!I\ I/BNPP#C1:Z*>RS5$B%O-+HQ2BUM
MIS)^F/;OPY8XG0A3$$Z[3?9&I\@:HJDK3<7Z@DIAVS.KO>-#G5!A+*N=(B7"
M2""3,,E+8(VB_IDLZ9*IA:URCF3TYKAG*[O7X J&=%!"FZR1Q'^K)#U*AO?,
MLF#C$V\J6S5ZI060RWN2AIE4CD V\*W<8PSO+\-%; \L]\MIX+H=LF?LD&1V
M)<\2CO9G$9#IG]8A[:Q]$"JJW9(C9;+$T (<C]F%JZIAE!K?5VG*,:1 AQ2T
MCB$%ZXDH9;XT!T<U?43E 1W(-0Q.8\JR!!/[9\.&0'N1M N)5BD.03$AT '&
MF14])&=<FC);JYX99+7]2^5E+O^K592,L-!P/K SQZU]L<1=66JL87W9G)VK
M7<8"]4E.Y#$[EL4J<BV15@47=:@%;$N4O#I] ;3]5I7ALHM+8;)--%5\PQ S
M[F1NT5*]\GO8-E4V45ZLAO.[2D^M.9FZ[<J]6KO$J(6@M$]*XS2$W:WR"&2Z
M5M=WUBJM6]A(>82GQO)]7+/MA;7[SUM@-5#5T20L_PGWE@6A9I<FD5?6+LID
M53>0C7SN+GV+Y0U,(A=>._%I>!]VH#@X .@D25%-X)I4:";()(CA)Z3.\:-R
MG5:RDP+4XB#])/F.:>' 7G$A[Y4T2L\Y@L42D.UBB]P>6Z>:8;MJG'AB<*]^
M@<KP4::6)DV6MD8XI7[IDTV+4J_UBDI+D>8<$7L<$8%?T\5H#[:JN8?)DHB,
ME&]-I4GLI7FRB!&@-[J 522G%#.UIXP*@Z'C-Y/T)PJ_ SD:)8FL$DC)DS4G
MJ?0P,X>5)VC5<:H[-RE*CR<<$ZI)V@!(4ZC<ZY.T",@TCJ(V\ 8"':I&*X;D
M@L.7F)KB.QP_(RN*W50*>EB%_&"@A#S[BI_(2HBP9$JD'B>I/ 0\'6!)\+J+
M$*XK_)%8BO5'I"M<A>G(0 .^%,XWYGJZ2)SU-:*!WSI.D542Z9$=,PI*AB'-
M;K9G,C,@0D@04)C#-WGLF9:%:Q;) %?$UHRXMCZHE(,P-V"36I*'7H&8LA7/
MM8R[E/B/42VJ(JO%2A!DX^R@0UVP(!0>A8WB%<& C04AD1UIK;7EH;+#27ZC
M2S_S76%5*FL2-,LPH:@92,:N8"4CTJ:H9#",Z9HB#*9X7\(E9SQ2\8&8"PYB
MV4H)HYVQOK[SLM%!A]FF5/AFJNJ8A%Q 7%5C,+]6BQA+Z'6Y9"VYUR(B09+I
M23@CX.1*:'C2F%,J)'W!#TVH+2;ULQE*3R&'X' MG0T!W/.O O"BX;Q%&0&)
M?9""&JKHG7K1%#7F0!-5%%FZ,/I>1'$@P /$0F=%R?3>>F)?PD)%WL'_[1G2
MT<(_>&'J_#=5_?K$=9=(I3F,:)(VMVO"Y*S9_^Y*$XB194>?(]QJX[A=KJ8O
M5"4M:C$VP(OF\FYD(00.5W =#[(-*MMBFI)L+E\<6.(W]B5("YFR9).E^@3Y
M*K*[=H%01'M8CEF3#C7F!]D(Y/I75!$27@?MB N@V]'90>EKI57K.E3*$"F?
MJZ3\NMU(FI@44<"2MZ2>IF9/B4!Q($DBC>5&7I=?5>P1AX%(1$H^)A@?&M["
M(:Q:2.+9>5"MLV"<M5$&(XP%1D<BGB#&3K3)/8QU2+'$=<;DD8@"99,/7(GK
MV+)$9@R T@?80,.@WDI9(^S[I^P24[W7#U._&,L.(RJF61B=5%, XQ/P)-TI
MVR-)M6-SU[^4=X/VP]J1D(:SJ'H0U>7*>4&/PO+X7,L-\4J:)W4& <DL W@M
M0V635'4=M=UPKLR 85:Q.7"1>65QF"5Q\Q8*)V]Z[FAC9VT5?ZDO8U>,C,@>
MU:G5"[9M#-**J;5ZZ631?K1,Q8N$\@9Q\UCV0SHW%*&6@ZLX]U+5_+'W77"8
M&]L@^*!+_0RLOB*U0Q% 6"V'BHRS1$0:DXP8HE'].YXCENX/A,^Q0U00EK3H
M6P9I^ZK%#\P. ^B5:3 E!;UO9^E*X(/+8SBHN3@._625W>9MUE&J9,)2'ED9
M-K@"ZE]%PHD"F([")0 S93.W;E2Q%CV3OE=Y_^;*-QZ._ SB[[_:9.]2D;U'
M9Q*5(*3>O"#"76$=7^NY WKE.=9/-N=P"04FN6WUE 7X;@4;'!CWD&&8ZI!U
M1%Y;*,CD)%3GC1DYJ^%<HNDI"!':F9++\$%98GR,SGO+*<*-O%@P,E79Y/:D
M@(@6MDGD^>HS"M]#2A-[L8R>0W]_J-((@H28D)P+T93LD8$TLPYL?Y%*A%>4
M-17*>$;BG6JP4C8"F45G,M-8O4>)=%R=7]/"5TC LV20WY&UVWA@*+9 ^I7L
MDOX9MFQJ.._4+-I,JP<Y^L>U?[R]9_[Q98G-EFB+#8<,VF1X!LR0P6.(GR+"
M[&;T+4B!@$&6.PFA<P&]CY9HX!4YJ&NZX9'\2(8=U]3[ME[2ZI,:6/51LE!*
MO4+"C<HI&!0QU^LE0H&%;9WWJ/KYH:E/JEH1<$!,GGIX$*_P4&0XC"YQ;6@=
M3#(H,%WUUBB-2H"O$28XS!JHPB"$ P0"RM'.Y-\KR?76B[?">LLFD+44A4D3
M6HOK7G5*Q(<5UOH<BU].&BU3S>#1F.4*J0K=W6;#)7"23(-/LMLXU0DGR^2X
M4%2@CCD)ZL9=.E4&)F_JR2TS\!)PM)19]63%^.^GMK/6"T=4R<9=5(,1R,[L
M@2Y3F+%R1HJ7,E[,A()OB4W66Y_WIZ;D6?=1:DJV.L>:DINL*<D%S3911E+L
M60V[66UUB?*!XI"+1ZZP^5TOX-?LM5:O';G\_A^I=N0^H=>[^Z27)8I&[F%M
MR-:9VVHNKDNZE2*CE3J_<WG;HHJ=#R^>NWOWU6ZZ<%5[6$=VGVC!A2^[?F''
M$$M7>IXDX$6KX[9ZK9<[C/[[ #0+U,(U$54J/IT)&IP+5*,(60]6GMO8T>PV
M/IZZS7LX\J.>SF;+/.^2,6(/XE=^2Y( C<V/'[*S ]:TF3"S2K.S',,<,')]
M*$^E&K>!5G6,U_ R<O/+BM16+)D=OY:I2I1?_#Q!&UQ+UKB6P50#FDJ.84V"
MJ^#1]#(J3ZEV)A8:@=L6$YT@(_,/9+JKY:Q0T1$JT35CFZS)HKFC6#HK6PP;
MAV4Z;<#*ON6%#<(TPXN#R:754:W!+H<K/0S*-S@;L&!268HXS$TT!/9U2HK,
MRCG(A3^BTIOHDE!!'-P#:VH>.GW!M1OK(E+@I+UH"HM33@U]4IR+/2DH\$?-
M;9\&S2@]JU8#<!A)I@O"I&P[Q)J':7*'K^N\8;481R<UU0?T:8-XY5BD"\I+
MC3^Y-IZG\IU;SG8T0-UPK@85#Y"U")@MDL 4U\SE4CH>%K/DZP]U!V-IDX>5
M%KFP UKDZBP8[D]+T <38:11N_D&TWC"TGKH0>L-#F+6?S,R*5;:D^Q5]J^#
MEU89NPP4=@U V1IO_L'5P[2\L#DQK+7?-)P+ZNUKNO%9LU@]1_'+5?9F.?-L
M>**.Y5C),YM@B5(LUUFZ\4/.N/E-$^",".]LX"&U<N8 OE2G8B7<T[=ZK54&
M@4FL%7"9X\T\Y#NX689UW)7[^\D>W_5\P)3(P!0]KHFA<TLK/&LV^LV@?C7\
MS2ERP.O_\,Q4&53G/I580,/Y/V):XB^Z0)]>#2<4UD8INJI\5W0OJSE@J/G7
M*(Q$':0,+926(544+J:BF+@3R(*//%GV%?,$& 0L<A#:@: 8WF15+2WB@7>;
M</$1*SBYKKB *@%MP$S7&(CM(%N*/$55BCNGREA.6>U9PJ,)S[?)EI:%3(0V
M!0-3^D$)KI*T E:N3!N(L4QY>(O)K3BR3.4OHRH6:JF206J6BGB$4>$RP]J.
MK?E;)=[8=!&N1)[J,TE%21X,TA"#7"HR;GEQL RST)(LH56"<KF84I$8[J0:
M8V39+46X6/=I%5JP<9PRC%49[E+U&,S2%"J^.T[H*ZX1K".'*H5HK&''6-0>
MZ8<Z21W PWJ%AES2&^A?'$+((?;42=TOJ!;(!&L:^W:7;9G/<<!DY/*'AS%:
MK,Z8U()2/H&52:/K85 U#SL"WD(6C[.Z*0[>P,KW"D^@O(>(K[V,8?.DSUE<
MXQ0AQ4TH%9++LWA6OV&LA^_CPKD.P-SH;K?49-FM?&<UP\4 644Y="5)*O*E
MR[U3?WCY)8?D68=HT4RS<:KXI,I@LAR-Y(K:"BM"X)9([%V2?F=IEOQL&D4)
M@S"&3N4WP^W(NIZ#@K+0_1&64*$I<7%.YF&92U@CJ'@4%$<]D;T 4^1+I+Q<
M.]^J^(_!RG"VZHFN$4"[+N^72QO(HH.X!!LHD)!S%Q:K^$0@AAAG]X+SL)FR
M4)72)'XYTS$Y036>MJU8%26SRI)K_5SR$%HRU]4DR@]KU<VQ%7MA;4(!/B5X
M4%FU$> /?,=XA<&-W)2!SQ(K!?&%S"<KAQ?QV]FSB-_G3_AU_[SO<7(7$\Q+
MX<NF_:!2"Y/\I4L%8EMSQ$%,_[G5 ?Y%7*J15:H9J:(:)PGF*85L$%21]/RJ
MJ@%)-(&9NYWHQ%0U2;%""A5_5)8'DO2X,*/5YX.T40S"K-\82SC<#\'(-S)/
M01-ER2/4%(T]O6O6%:SV)783>SJ:4D,D*252Q@G3/1:Q[=3<6G9<KB)?MK)D
M5#JC2N_Q%CC#EP-%7!5;GF1<W(:3H$L)9]BR:"@X;U'HK.AJ'9:C:$<9A::H
M3GT::,D1<&^P<EA3^([#4?L"M?A58F_+;>9;9XWSQPBUO>>DSI:I%7!_]?J%
MD'*,V#U&[!XC=C?BR'\K2S9XLC$!H$:L6C92W:UC).^A1?*V6AVWW>KN82SO
ML^@#?^%S7PQE^!B;<D.J%)YIYW=H;>+)W-VN2A-/W2C^H'@"IHP_E!L<HP0?
MZ6AV&ULWP4EV+DYP;^M.79F:20=?=\J.J^ "49FT7<]6EJJI&[5,S2BJ&" M
MWFA9T7:Z>:X9G5-O2G/,+.;0K2\F4YGB&;-B/)9=?V;OK2Z7V=5U$^;4,I M
MVT9JD)+]19>2L3^98Y19(<]?)TNW#SPS&M;2:#;7,K2T.HU.;[XQ99&A9;$1
MYKQWOGGS3:MQ<KZ>56@+BSUM])K=?5GL7IWL2>/D=*].]F03)L<5+(OWIU:>
M+I.\MX/&QAG.]##+XUX:7$D*G6O >"(;]=**Q(X?YA=0:RC"\P^633Z"&/F0
ML[W_7)[\U!?J_$\:HW'OE70ZZ"16X2P7MT/GF^HPN8SDO=5EUP$0QW0\#S#:
M0>3]+<5"K^^4,_F"G,G/#'MW\-CM''HX<UC8?Q;GT._GR>\;W?PL<HT+.T\M
M*[AJ".6Z]00V?\7;,/V^TU&\&&EJ2M9&F.FY%GXM6VWEL8YX]\SKI\Z_L4#F
M\30W<IK-1O/QSG,S9_@,/6$K;'ZWP:=UXIXW=[+HT1&$CR"\9)$E@N%Y19:.
MX'L$WUT&W_5B@W:A[MRSB%O[RG7D4RPFAHETZ\E13Q-]O'O V^H]0/@\U$/K
M-%I/<&K/,Y*R[7;.5XW,VF <Y?&2EI+(VFZKW5U>(#M>T%-CT>FJ*M^68Y$W
M9?0YCK%1M>,8('V0951;YVY[92Z\ W54C\AQ1(XG,$>=N\U5I)\C8AP1XQ 0
M8W6A<P<PHSZE1BVYE''R*-UX-U&4>Z9*@3H9U0>P;=K"/9^\"SLRIMSAKVEZ
M)2[9X<_.N[$JU-7.(/M9_G)VVCC3.1CN/7]3D,$OIXV.^<5>689+PQ"KZMHZ
M]-\N_;?'62+PKQ/7ZHX;3;>1?;,SZ6,7OI\6<*L?33'BC2#*<THKNZBOQ>O*
M9"[80QA@%295'4@5=I9EW;A7.U;2PQJ1$Y'ZLB9HGN0U7V$Y:*NWI2<O:.)-
MTP1K1&'B+N6TB?$D2J9"Z+<K!:5_:74:)[KKZ>/7]=\9F+[.$_\[$20@.>70
MO\/.B<1:TW$"*X#S><5%]GWKE)Q)Y&&-L5%R)[!NJJI2I@!-EQ15XV$ELM /
M)UQGS'F'$7NQT,5K[YN'LRAEIV)-T(>I%W/; "#2>1I2#24:2I:R?"%KG7^[
M_B.3U<U?+FCJ^_Q3*!G>2R>LV"T5HO*384SE?X$8T>ERWPF[:*CJ!2U+4<@2
MR'Q!GH& :I\,=7>P\-O0EW5#92TM=9_>G9<&#<>YY()GN?<#^'\L!GB5%IW+
M9C>!1<]DW6WN6.]Q%=(PIE+87!A3]UWPD)T3\8/)/B3I0(18V8QKIP$5E>6_
M<5F4[ MKFW(Z[^,+ (=7R++[; M9[A)VJXX>I:?4?UV3;+M6KQ-@86>%<18E
M+Y6@Q%+0W'%"5H VQ21KD%2M1?=L\9BFO +1$'[ G[G<I.>/ #$7[$8J'ZNV
M%W^0N/IH_=WG=([?4DI$I^&\99KK?$7>>Y2'2'X)$L&U_ZF$)]:Q'E#7"!]&
M2<-^D7.?^3Q4A9K@[-87C_#15R_EPO;+3.6\L#J[=)NM%]]?TO49H>=2\64]
M%8I.6$&>6DYQ'QXY@7"*"?YPVBOI(' X:0D?7;O<ZY7L1^M\XTY'SK7D]$H(
MN_IVK9:#>Q)IZF$%A7$HJZ.6C0/8?"HK[3E3E,C:GZ$E6NXHRP5Q^=QF)LG]
M$4S3:]H;%4!_]'A:1"T=/Y_/R>SQR"J[]B+*4UHRUB^M1E=3,)Q74K>EZH;B
M2[1\JE=^SS'-%UL>2N>>&B<7FN>6W<R62&L76V\ 9 CG!B3;+1#6G5&[K6.X
M9* _K%Z"2!Z26$CE->330'5'D8 74N]YR=T.8E!;"JK*R3J,:0!T#Y6XPS8A
M7B;+YF0K51,NP6&;3?+'LKO'LKL[679WWQHQOY.F7(/[961\E#2\$DP=0DCZ
M!X&MF**EW:3+QB'NW$:7]Y+7;7&WO=VMEGO>Z^QOE.4^P,\UZ&#SJ\4L"MVM
MV>R>A.YVW59OS3B*74@)>DB@]0,"A';O'ELG;JNY)GW8L:RO/:0<[U4'6R/)
MP.!*?ZGJ&$>QYA'%FF>>:O'B]/1T*YDPAX#&AR@ O&B=GZT<7'QD_;MT@^>G
MO95)PI'G/_38;R@:;=9LN950[6>FGQ].%'NKY[;:9\\MD'U>6,UB=T7%<]6;
M%Q2P,TZ,.13@H>X*+Y/-C-$V2E%;%!?&O171:U)PP?Y0-F?/0&PI\B2=.@.6
MB>TUR::FCN#FV:45J#],/P'NP_T %TGGV+3PZ#TY>D^>@G5<S1(>+]<DP!"%
MM$:I>;B]X?F+'7LN6+3=9J]]+ .U14M"R1KH8D4H#'2HX='23GA@IJR.VSQK
M'3U:CPJ&(R\5-1DEAV;C.M]%"]<^ =(7S* C$K8$Z*P'(<!MMN4#74B$UH,$
MWLW!$)JC,>QH##L:PY9OE'I,@JN]_KU/@MN9X'(=D6"BS)>M5/!LTY@R6!>E
M]DDSJ@D^#]1I(>M2C5/C<H6 ND:J9*M=,[*\#NN>V#;::_1:G;5LH\W&2?-T
MX[;1=J/9Z6W>XMIM-'MGN]:S<2D]X&AJW0W!Y/TL?7AP2-?3-)U9)2QLGVYD
M9<O&_:BYK/:Z<V<Q3Y78(\F_?;)8[#\:_%:PT^@:2"LBQOJDZGF:#4]/5PVH
MWJ'PN'V 5LU64\Z6/S8P6-V)<K)?'A2Q9R#*!#5.XE>!" H_#U%!4_0UJBD"
MN")Y%1L@K]4SW1/07:/B=PWT'#TS"* U!HP'2,(;\^EL]61.%I/&HTBYBFMG
M/0![5(GR607QM]Q6]W0/HW7V"9+_VXL*61$)S;5>["_%MY\WE5RF7^"15*YM
M)G3(#T4E_M8 O2/]/-+/W3GC$GA;NL^RIO!5+-Z/G.^\E\1ED@H_/!KSUHP!
M/#D_.48!/NP,2STPJ&9;[L5#-HD<=4Z"LEYG+I0=I:AE6RB+B1<&6Y>/]A'\
M6MWVD<AMW*"VFIWWF5.XUI&^;=R@M@%'PE$KK 56M[-*<8RC1KC:^7X6^89=
M#V7][Y#S )Y_N/^+=GM^Z:&="^>O0*ZJ4M'"'FY['AS]5O4/D-4D@"!Z41*;
M1B1.D7$/E$#D(AW# /1J4%?VSBWU=) MM"CW5;<>BA(@$U2B/T6GNE YL2Y.
MG@O725('&ZI$."*%1,L)PIC#KC$V.ROZF?BKP!H9U-.PX53,?\^_<=L?L>JI
M@47DO\J$C_EA_L\NJO^3-Q01=L"0Y5:H:0^ V2!)Q]3^"J P%2,19]A*,!6W
M(<R+AHN<&VNI'!F.]N>PCDQ66I'56N M'GPH8K_2:[#0YU\:K.$P0A431JE,
M38U)X'._XC+UUN@V&N'R[OLTQ-L(!Z%J*V0C<M_+POLQI(ZT[4/CA84!Z[T&
MGN(XS,>4[8$G^:YTH9M&EYD&'">+3G'[5.2;&!8 =%@JY"K+B@5I0JOM;%^)
M"J8*P2! 6@)G)+PH'_G8$@\6!NN$0PHSN^-/7(P%Z!"9$WEW#%TIGZ=IM"/?
MIDRCK !N6O<J4)E;3+'N%SEUX,,V2]07B(B!BVUN@/5F/  P5;A;(&M%"MP2
MZ98(9 <AUQGB0#%U1;*6#XQ\F'ICJ\D2=U"BYH2$&BXV"@3"*7M.IN&MYS/E
MR81?I&$^Q3[ X;A?I!DW74("B0/AOV5+PXR[!G^BQFG8=D/_ 1+:(/4*[DWL
M]4&B:#A?=!]%+\,A;JDR!K'STCYDKT(6)T 6P#)5<"YW83Y2K8GQ+L+X%MLI
M#SU-TW_]N7OZ!E8)C$$,]4$C%8U1$ $*FI'Y^C9,U#U@B8[R.NE? R^"?_F1
M%XXSAXOKB-(4]EWVI_;1)^G0BZ79G.\]I)M#F>42*!&EEU'K6WQ[@ HI[H::
M;/'"$ :(C]1"SMB;8HMH\8.ZVP5<,LRZ9]@H<(R%8)'I+E;,>[#95H9BV$3$
M\&[(?]BM+-%(.]6L,A6^ !8;F')EUG0$)L@! 4V /_=#N(Q@!G"(3$^B$'WC
M?+,+< 6;7@D;#0<%-J^T9Y7<GH\;4 =6H##$:MZ7&N*'0(:#%_'W.+F+<<-%
MC IMFG,OT'P$J)\#J=E&!^Q=H8Y7(%H %^"#U*<WT\L-85+\$*D?(M9(H24(
M,Q][MB6QAW6I<%0\;I#]2[?+;1H9; G59:&[,(4;GR"X9-(!11 B) JY$C[Q
M;;5$H"965USJA@K7ROV@%57#7S(1_H=J]<F'=[CLW/L>JKYB2:1V:*6'6I7]
MRMM_? "98<7MG14R"&P^ OF-YNZFG'^\L%_9ON*-U?Y.=].K:\:+X.R%42E9
M.0VS[P1BNE-ZP_E A#9$K3NA_R_KW64AY=9+D?AJ$D<= 9F5P1/"+U-GDB05
MP(-QF&4*ME%ATGT;J0[,79)^5_V,T\Q@%?$=I.97;$Z(4:+ 7H H->!0?2Q<
M*;**G4 R$"3(DR15K8X)\='JX.6CS&KECG> ^P'Z0%H/_NLVB6Z)IS-? 1(_
M2I#VD.P&+%G@0R77]:<E='6ND9"8T1(?2 61#^!70]0=CU4:3*>)8Y6&]4A
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ME4PBY^$8Z'\/,] .T=,636<=0X1I2B0S"A4YE!8+CPBH&8R->$.V B9UWF
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M&BT'KC$B+:RN+&2%6/*ZM;_"V%&98H3*Y<'<&PD".=4FWA3%,[>NWHBMWR>
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M_9^:^B0Z>W;L:'2JJ>K'GV:?H\$C/#KPH\@?GZI-M0L/1^Q'=$)=Y]$[Y23
M*T,?");O6+[K!Z<_J_S/&7YS,J1CQYV>_OW!&;.07+-G<N>/J?=W):1>>!*R
MP!F*!T/G/PR& 9WP7Y_E$*$=U_%8,F1-;\,X+W^,G($3D5ZOJ?_Z"SZ?$+I
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M9T">'7A:OJR0'(N3!B\],+L."Q,^*RA\$Y>AP#@@']3Z*W9"AT\1R,HUQ9]
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M<^GFLB8@G)M.Y<+TI3$;#&L([:X&D\<+J26WTV233#&EN2 NUQY\SHHR3!Q
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M1.*4YS5 _9:NI"5+:-DK= "&/HZ6OU*T^+;<F.7_'@5)&Q,(:TX&,!??3[A
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MMSXYO_GV^>H:/KI_Z#]<?KN\?B W7\C5-7Q^>? $ 0GDX>LE^?=E_XY<7E\
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M"WB*>KQR!- ()ODSJ$0LJT E.A"*^BJ2.V%>K L+S(K[ME.5%48Z43&N5,_
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M'[R1_$#F_C0^J$VS79!J6GH0I00'&7X9^/84_AE%8_>W_P%02P$"% ,4
M"  KH6)7)5+;F2(0  ";?@  $               @ $     979H+3(P,C,Q
M,3 R+FAT;5!+ 0(4 Q0    ( "NA8E=MDPEV;0(  'P'   0
M  "  5 0  !E=F@M,C R,S$Q,#(N>'-D4$L! A0#%     @ *Z%B5Y,E'$V0
M"@  $V$  !0              ( !ZQ(  &5V:"TR,#(S,3$P,E]L86(N>&UL
M4$L! A0#%     @ *Z%B5]V^#%W0!@   3,  !0              ( !K1T
M &5V:"TR,#(S,3$P,E]P<F4N>&UL4$L! A0#%     @ *Z%B5RNZV'_M @
MQ @  !L              ( !KR0  &5X:&EB:70R,S%M87)C=6UC;VYS96YT
M+FAT;5!+ 0(4 Q0    ( "NA8E?=7";R_%4  )$@ P :              "
M =4G  !E>&AI8FET.3DQ,C R,FYI86%U9&ET+FAT;5!+ 0(4 Q0    ( "NA
M8E>K:-"2T"H  /;] 0 9              "  0E^  !E>&AI8FET.3DR;FEA
B<')O9F]R;6$N:'1M4$L%!@     '  < V $  !"I      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
